



(11) **EP 1 644 485 B9**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

- (15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Claims DE 28
Claims EN 28,31-33
- (48) Corrigendum issued on:
04.01.2012 Bulletin 2012/01
- (45) Date of publication and mention of the grant of the patent:
04.05.2011 Bulletin 2011/18
- (21) Application number: **04740821.6**
- (22) Date of filing: **08.07.2004**
- (51) Int Cl.:
C12N 5/0735^(2010.01) C12N 5/10^(2006.01)
- (86) International application number:
PCT/EP2004/007529
- (87) International publication number:
WO 2005/005662 (20.01.2005 Gazette 2005/03)

(54) **SECRETED PROTEINS AS MARKERS FOR CELL DIFFERENTIATION**
SEKRETIERTE PROTEINE FÜR ZELLDIFFERENZIERUNGSMARKER
PROTEINES SECRETEES COMME MARQUEURS DE DIFFERENCIATION CELLULAIRE

- | | |
|---|---|
| <p>(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR</p> <p>(30) Priority: 08.07.2003 EP 03015400
08.07.2003 US 485462 P</p> <p>(43) Date of publication of application:
12.04.2006 Bulletin 2006/15</p> <p>(73) Proprietor: AXIOGENESIS AG
50829 Köln (DE)</p> <p>(72) Inventors:
• EHLICH, Andreas
53894 Mechernich (DE)
• BOHLEN, Heribert
50733 Köln (DE)
• SCHWENGBERG, Silke
52355 Düren (DE)</p> <p>(74) Representative: Steinecke, Peter
Müller Fottner Steinecke
Postfach 31 01 40
80102 München (DE)</p> <p>(56) References cited:
WO-A-95/14079 WO-A-98/49320</p> | <p>WO-A-02/051987 US-A1- 2002 042 096
US-A1- 2003 008 836</p> <ul style="list-style-type: none">• MUELLER M ET AL: "Selection of ventricular-like cardiomyocytes from ES cells in vitro" FASEB JOURNAL, FED. OF AMERICAN SOC. FOR EXPERIMENTAL BIOLOGY, BETHESDA, MD, US, vol. 14, no. 15, December 2000 (2000-12), pages 2540-2548, XP002180458 ISSN: 0892-6638• WOBUS A M ET AL: "RETINOIC ACID INDUCES EXPRESSION OF THE VENTRICULAR 2.1 KB MYOSIN-LIGHT-CHAIN-2 PROMOTER DURING IN VITRO CARDIOGENESIS OF EMBRYONIC STEM CELLS" CIRCULATION, AMERICAN HEART ASSOCIATION, DALLAS, TX, US, vol. 92, no. 8, SUPPL 1, 15 October 1995 (1995-10-15), page I114, XP002001047 ISSN: 0009-7322• WOBUS A M ET AL: "RETINOIC ACID ACCELERATES EMBRYONIC STEM CELL-DERIVED CARDIAC DIFFERENTIATION AND ENHANCES DEVELOPMENT OF VENTRICULAR CARDIOMYOCYTES" JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, XX, XX, vol. 29, no. 6, 1997, pages 1525-1539, XP001030714 ISSN: 0022-2828 |
|---|---|

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 644 485 B9

- KLUG M G ET AL: "GENETICALLY SELECTED CARDIOMYOCYTES FROM DIFFERENTIATING EMBRYONIC STEM CELLS FORM STABLE INTRACARDIAC GRAFTS" JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, vol. 98, no. 1, 1 July 1996 (1996-07-01), pages 216-224, XP000670716 ISSN: 0021-9738
- BRONSTEIN I ET AL: "CHEMILUMINESCENT REPORTER GENE ASSAYS: SENSITIVE DETECTION OF THE GUS AND SEAP GENE PRODUCTS" BIOTECHNIQUES, EATON PUBLISHING, NATICK, US, vol. 17, no. 1, 1994, pages 172-174,176-177, XP009011110 ISSN: 0736-6205
- HUNTER J J ET AL: "VENTRICULAR EXPRESSION OF A MLC-2V-RAS FUSION GENE INDUCES CARDIAC HYPERTROPHY AND SELECTIVE DIASTOLIC DYSFUNCTION IN TRANSGENIC MICE" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 270, no. 39, 1 September 1995 (1995-09-01), pages 23173-23178, XP002001049 ISSN: 0021-9258
- LIU HSIAO-SHENG ET AL: "Is green fluorescent protein toxic to the living cells?" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 260, no. 3, 14 July 1999 (1999-07-14), pages 712-717, XP002257794 ISSN: 0006-291X cited in the application
- GUAN K. ET AL.: "Embryonic stem cells in vitro - Prospects for cell and developmental biology, embryotoxicology and cell therapy" ALTEX, vol. 16, no. 3, 1999, pages 135-141, XP009018838 cited in the application
- METZGER JOSEPH M ET AL: "Vital staining of cardiac myocytes during embryonic stem cell cardiogenesis in vitro" CIRCULATION RESEARCH, GRUNE AND STRATTON, BALTIMORE, US, vol. 78, no. 4, 1996, pages 547-552, XP002213275 ISSN: 0009-7330 cited in the application
- ROHWEDDEL J ET AL: "EMBRYONIC STEM CELLS AS AN IN VITRO MODEL FOR MUTAGENICITY, CYTOTOXICITY AND EMBRYOTOXICITY STUDIES: PRESENT STATE AND FUTURE PROSPECTS" TOXICOLOGY IN VITRO, ELSEVIER SCIENCE, GB, vol. 15, no. 6, 2001, pages 741-753, XP001027083 ISSN: 0887-2333

Description**Field of the invention**

5 [0001] The present invention relates to the use of proteins capable of being secreted across the cell membrane as cell type-specific reporters during cell development. In detail, the present invention relates to embryonic stem (ES) cells stably transfected with a DNA construct comprising a DNA sequence encoding a secreted protein, which is operably linked to a cell-and/or development-dependent promoter; a method for preparing such ES cells; a cell culture obtainable by culturing said ES cells; a method for the toxicological examination of substances using such cell cultures as well as
10 to methods for the identification of differentiation and growth factors for induction of selectively differentiated cells which can be used as a source for tissue grafts; a method for producing transgenic non-human mammals using said ES cells; a transgenic non-human mammal obtainable by said method; and to a method for examining stages of cellular development using cells of such a non-human mammal. The present invention also concerns assays to identify culture conditions and substances that promote the differentiation into a desired cell type, or to determine the toxicity of a
15 compound for certain cell types. Those assays are particularly suited to give indications of possible developmental and differentiation disturbances during embryogenesis.

Background art

20 [0002] Precursor cells have become a central interest in medical research. On the one hand precursors can replace cells that are senescent or damaged by injury or disease and on the other hand these cells represent an ideal model for studying development and differentiation and the factors influencing these processes. Employing conventional cell lines for these studies has the disadvantage that individual cell lines may not be fully representative of the complex biology of an intact organism. Moreover, even repeating the tests in multiple cell lines does not reproduce or account
25 for the complex interactions among cells and tissue that occur in an organism.

[0003] This is the main reason why toxicity testing in cell lines can not replace conventional animal tests. New chemical compounds are constantly being developed and tested on animals. In addition to industrial and household chemicals, a number of chemical compositions are developed each year for use as pharmaceuticals. Rules regarding the testing of potential pharmaceuticals are promulgated by the Food and Drug Administration ("FDA"), which currently requires
30 comprehensive testing of toxicity, mutagenicity, and other effects in at least two species before a drug candidate can be entered into human clinical trials. Preclinical toxicity testing alone costs some hundreds of thousands of dollars. Despite this huge investment, almost one third of all prospective human therapeutics fail in the first phase of human clinical trials because of unexpected toxicity. It is clear that currently available toxicological screening assays do not detect all toxicities associated with human therapy or exposure to chemicals in the environment. Better means of screening
35 potential therapeutics or chemicals in general for potential toxicity would reduce the cost and uncertainty of developing new therapeutics and materials, for example for use in medical devices or in other devices or goods humans are exposed to every day.

[0004] The detection of teratogenic and/or embryotoxic properties of chemical agents occurs presently by determination of the reproduction toxicity of test substances following single or multi-administrations to pregnant laboratory mammals and by tests of the embryotoxicity in the early stages of pregnancy. Furthermore, in vitro tests are performed with mammal embryos (Neubert and Merker, de Gruyter, Berlin-New York (1981)) and with embryonic organs for teratogenicity tests. These test procedures have however the disadvantage that they require the use of a large number of live mammals, in particular rats and mice. In vitro test procedures, in which primary cell cultures of limb buds (for example, "Limb Buds", Kochhar, Teratology 11 (1975), 273-287), or brain parts of embryonic rats (Flint and Orton, Toxicol. Appl. Pharmacol.
40 76 (1984), 383-395) or permanent cell lines of embryonic or adult mammal tissue such as tumor cells of the ovary or embryonic palate cells are employed, do not fulfill, strictly speaking, the requirements which are imposed on the teratogenicity tests during the embryogenesis, namely giving indications of possible disgenesis or developmental disturbances.

[0005] Efforts have been made for a couple of years to employ permanent cultures of totipotent/pluripotent embryonic stem cells (ES cells) for the detection of embryotoxic and mutagenic substances; see, e.g. Laschinski et al., Reproductive Toxicol. 5 (1991), 57-65; Newall and Beedles, Toxicol. in Vitro 8 (1994), 697-701; Sehlmeier and Wobus, Mutation Res. 324 (1994), 69-76.

[0006] All those systems make use of the biological properties of the test ES cells or of a reporter system that has been introduced into the cells.

55 [0007] For example, US-A-6,498,018 describes a method for determining the effect of a biological agent by contacting a cell culture with a biological agent. The cell culture contains human multipotent CNS neural stem cells that are derived from primary CNS neural tissue and a culture medium with pre-selected growth factors. The read-out is provided by the effect of a biological agent on the presence or absence of a biological function or property ascribable to the cell culture.

A major disadvantage of this system is the fact that particular biological functions or properties inherent to a certain culture of cells are difficult to measure and often involve the destruction of a large part of the culture in order to obtain enough material for the assay.

5 [0008] WO02/086073 discloses a method for the positive selection of neuronal cells differentiated from nuclear transfer embryonic stem cells by taking advantage of the neural stem cell marker nectin. This method is limited to neural cell types expressing nectin naturally. US-A-6,007,993 describes an in vitro test procedure for the detection of chemically-induced embryotoxic (for example also teratogenic) effects based on differentiated pluripotent embryonic stem (ES) cells from the mouse and rat and using embryonic germ (EG) cells established from primordial germ cells. Stable transgenic ES or EG stem cell clones are constructed, wherein a bacterial reporter gene, LacZ or the luciferase gene, is brought under the control of tissue-specific promoters or developmental control genes. Following differentiation of the ES cells in the presence of teratogenic substances into the different germination path derivatives, there occurs a differentiation-dependent expression in the cells, due to the activity of the tissue-specific promoters. The activation, repression or modulation of these tissue-specific genes is detected based on a reaction depending on the reporter gene employed, for example the X-Gal assay.

15 [0009] Wobus et al., J. Mol. Cell. Cardiol. 29 (1997), 1525-1539 described a method for the monitoring of cell differentiation including culturing embryonic stem (ES) cells capable of differentiating and forming embryoid bodies, which contain a recombinant nucleic acid molecule comprising a reporter gene encoding the lacZ gene under the control of MLC-2v promoter region, wherein the amount or activity of the lacZ gene product is used for monitoring the differentiation of the cells in the presence of a retinoic acid.

20 [0010] WO99/01552 discloses embryonic stem (ES) cells, which are transfected in a stable manner with a DNA construct encoding a non-cell-damaging fluorescent protein and operatively linked thereto a cell- or development-dependent promoter. Also disclosed is a method for toxicological monitoring of substances using these ES cell cultures.

[0011] Although the above described methods employ semi-quantitative as well as relatively simple and robust assays, those assays usually involve the destruction of the tested cells. The preparation of a cell lysate required by many of the described conventional assay systems results in a high intra- as well as inter-assay variability. For repeated measurements during the course of differentiation many parallel cultures have to be assayed with the associated problems of variability. Laborious preparation of lysates also renders the assay less amenable to high-throughput formats. Using fluorescent reporter proteins can overcome some of those problems. However, GFP expression has already shown some toxic effects (Liu et al. Biochem. Biophys. Res. Comm. 260 (1999), 712-717). Another disadvantage is the autofluorescence of aggregates of ES cells (embryoid bodies) which gives a high background in fluorescence measurements.

30 [0012] The technical problem of readily monitoring cells differentiating into a certain cell type and thereby providing a reliable and highly sensitive test system for toxicity screening, differentiation promoting agents and/or appropriate culture conditions, medium supplements, is achieved by providing the embodiments characterized in the claims, and described further below.

35 Summary of the invention

[0013] The present invention relates to a method of monitoring cell differentiation comprising culturing cells capable of differentiating into at least one particular cell type, wherein said cells contain at least one recombinant nucleic acid molecule comprising a reporter gene encoding a product that is secreted upon cell differentiation, under conditions allowing differentiation of the cells, or maintaining a non-human animal comprising such cells under appropriate conditions; and determining the amount of activity or amount of the reporter gene product either within a body fluid of said transgenic non-human animal or the cell culture medium or sample thereof.

45 [0014] The present invention also concerns the mentioned reporter gene constructs for monitoring cell differentiation, as well as cells, aggregates of at least one cell type, tissue comprising those cells or aggregates, organs comprising said cells or tissue, implants and transplants comprising said organ, all of which are characterized by comprising such a reporter gene construct.

[0015] Furthermore, the present invention relates to a non-human animal and a composition of matter both characterized by comprising a reporter gene construct, a cell, a cell aggregate, a tissue and/or an organ described herein.

50 [0016] In addition, the instant invention relates to an array or chip which contains the cells, cell aggregates or tissue of the invention attached to a solid support or suspended thereon as well as to an apparatus for analyzing said array or chip.

[0017] In particular, the present invention relates to test systems to identify substances that influence the differentiation of cells into certain cell types. Therefore, the present invention provides a method for obtaining and/or profiling a modulator of cell differentiation. This method comprises contacting a test sample containing a cell, cell aggregate, tissue, organ or a non-human transgenic animal as defined above with the substance to be tested; and then determining the effect of the test substance on the amount of the reporter gene product or activity compared to a control sample or animal.

55 [0018] The test system provided by the present invention is useful for drug screening purposes. It is envisaged to obtain and manufacture drugs which promote or inhibit the formation of said specific cell types using the method described

above, wherein an enhanced or reduced level or activity of the reporter gene product is indicative for the drug. An enhanced or reduced level or activity of the reporter gene product, respectively, can also be indicative for an agent or compound which supports wound healing and/or healing of damaged tissue or toxicity of compounds, respectively.

[0019] The present invention additionally relates to a kit useful for conducting the methods described above, which contains, for example, a reporter gene construct and/or a cell as defined above, and standard compounds, like cell culture media, selection agents, detection agents for the reporter molecule and control samples.

[0020] Furthermore, methods of conducting a drug discovery and/or a target discovery business are disclosed. Both methods involve providing one or more assay systems described above for the identification of modulators of cell differentiation; and/or conducting therapeutic profiling of the modulators identified, or further analogs thereof, for efficacy and toxicity in the transgenic animals provided by the present invention. The modulators identified using the methods provided by the invention are then either formulated in a pharmaceutical composition or licensed to a third party for further drug development and/or sales.

[0021] The present invention also relates to modulators of cell differentiation which have been identified using the methods of the invention as well as to pharmaceutical compositions comprising such modulators for use in the modulation of cell differentiation and the treatment of corresponding diseases.

[0022] Furthermore, the present invention relates to the use of a reporter gene construct, a cell, a cell aggregate, tissue, organ, implant or transplant, a non-human animal, a composition, an array or an apparatus provided herein in drug discovery, pharmacokinetic or pharmacological profiling.

Brief description of the figure

[0023]

Figure 1: SEAP expression driven by the cardiac-specific α MHC promoter by cells differentiated from ES cells in the presence of retinoic acid. ES cells transfected with the α -MHC-SEAP vector (containing the SEAP gene under the control of the heart-specific α MHC promoter) were differentiated in the presence of all-*trans* retinoic acid at concentrations indicated. After 13 days culture supernatants were assayed for SEAP activity. Shown are mean values of duplicate samples from which background SEAP activity was subtracted. Activities are expressed as percentage of SEAP activity in samples containing only solvent (DMSO) but no retinoic acid.

Definitions

[0024] For the purposes of this description, the term "stem cell" can refer to either stem cell or germ cell, for example embryonic stem (ES) and germ (EG) cell, respectively. Minimally, a stem cell has the ability to proliferate and form cells of more than one different phenotype, and is also capable of self-renewal, either as part of the same culture, or when cultured under different conditions. Embryonic stem cells are also typically telomerase-positive and OCT-4 positive. Telomerase activity can be determined using TRAP activity assay (Kim et al., Science 266 (1997), 2011), using a commercially available kit (TRAPeze(R) XK Telomerase Detection Kit, Cat. s7707; Intergen Co., Purchase N.Y.; or TeloTAGGG(TM) Telomerase PCR ELISApplus, Cat. 2,013,89; Roche Diagnostics, Indianapolis). hTERT expression can also be evaluated at the mRNA level by RT-PCR. The LightCycler TeloTAGGG(TM) hTERT quantification kit (Cat. 3,012,344; Roche Diagnostics) is available commercially for research purposes.

[0025] In accordance with the present invention, the term embryonic stem (ES) cell includes any multi- or pluripotent stem cell derived from pre-embryonic, embryonic or fetal tissue at any time after fertilization, and having the characteristic of being capable under appropriate conditions of producing progeny of several different cell types that are derivatives of all of the three germinal layers (endoderm, mesoderm and ectoderm), according to a standard art-accepted test, such as the ability to form a teratoma in 8-12 week old SCID mice.

[0026] "Embryonic germ cells" or "EG cells" are cells derived from primordial germ cells. The term "embryonic germ cell" is used to describe cells of the present invention that exhibit an embryonic pluripotent cell phenotype. The terms "human embryonic germ cell (EG)" or "embryonic germ cell" can be used interchangeably herein to describe mammalian, preferably human cells, or cell lines thereof, of the present invention that exhibit a pluripotent embryonic stem cell phenotype as defined herein. Thus, EG cells are capable of differentiation into cells of ectodermal, endodermal and mesodermal germ layers. EG cells can also be characterized by the presence or absence of markers associated with specific epitope sites identified by the binding of particular antibodies and the absence of certain markers as identified by the lack of binding of certain antibodies.

[0027] "Pluripotent" refers to cells that retain the developmental potential to differentiate into a wide range of cell lineages including the germ line. The terms "embryonic stem cell phenotype" and "embryonic stem-like cell" also are used interchangeably herein to describe cells that are undifferentiated and thus are pluripotent cells.

[0028] Included in the definition of ES cells are embryonic cells of various types, exemplified by human embryonic stem cells, described by Thomson et al. (Science 282 (1998), 1145); embryonic stem cells from other primates, such as rhesus stem cells (Thomson et al., Proc. Natl. Acad. Sci. USA 92 (1995), 7844), marmoset stem cells (Thomson et al., Biol. Reprod. 55 (1996), 254) and human embryonic germ (hEG) cells (Shamblott et al., Proc. Natl. Acad. Sci. USA 95 (1998), 13726). Other types of pluripotent cells are also included in the term. Any cells of mammalian origin that are capable of producing progeny that are derivatives of all three germinal layers are included, regardless of whether they were derived from embryonic tissue, fetal tissue, or other sources. The stem cells employed in accordance with the present invention are preferably (but not always necessarily) karyotypically normal. However, it is preferred not to use ES cells that are derived from a malignant source.

[0029] "Feeder cells" or "feeders" are terms used to describe cells of one type that are co-cultured with cells of another type, to provide an environment in which the cells of the second type can grow. The feeder cells are optionally from a different species as the cells they are supporting. For example, certain types of ES cells can be supported by primary mouse embryonic fibroblasts, immortalized mouse embryonic fibroblasts (such as murine STO cells, e.g., Martin and Evans, Proc. Natl. Acad. Sci. USA 72 (1975), 1441-1445), or human fibroblast-like cells differentiated from human ES cells, as described later in this disclosure. The term "STO cell" refers to embryonic fibroblast mouse cells such as are commercially available and include those deposited as ATCC CRL 1503.

[0030] The term "embryoid bodies" (EBs) is a term of art synonymous with "aggregate bodies". The terms refer to aggregates of differentiated and undifferentiated cells that appear when ES cells overgrow in monolayer cultures, or are maintained in suspension cultures. Embryoid bodies are a mixture of different cell types, typically from several germ layers, distinguishable by morphological criteria; see also infra. As used herein, "embryoid body", "EB" or "EB cells" typically refers to a morphological structure comprised of a population of cells, the majority of which are derived from embryonic stem (ES) cells that have undergone differentiation. Under culture conditions suitable for EB formation (e.g., the removal of Leukemia inhibitory factor or other, similar blocking factors), ES cells proliferate and form small masses of cells that begin to differentiate. In the first phase of differentiation, usually corresponding to about days 1-4 of differentiation for humans, the small mass of cells forms a layer of endodermal cells on the outer layer, and is considered a "simple embryoid body". In the second phase, usually corresponding to about days 3-20 post differentiation for humans, "complex embryoid bodies" are formed, which are characterized by extensive differentiation of ectodermal and mesodermal cells and derivative tissue. As used herein, the term "embryoid body" or "EB" encompasses both simple and complex embryoid bodies unless otherwise required by context. The determination of when embryoid bodies have formed in a culture of ES cells is routinely made by persons of skill in the art by, for example, visual inspection of the morphology. Floating masses of about 20 cells or more are considered to be embryoid bodies; see, e.g., Schmitt et al., Genes Dev. 5 (1991), 728-740; Doetschman et al., J. Embryol. Exp. Morph. 87 (1985), 27-45. It is also understood that the term "embryoid body", "EB", or "EB cells" as used herein encompasses a population of cells, the majority of which being pluripotent cells capable of developing into different cellular lineages when cultured under appropriate conditions. As used herein, the term also refers to equivalent structures derived from primordial germ cells, which are primitive cells extracted from embryonic gonadal regions; see, e.g., Shamblott et al., (1998), supra. Primordial germ cells, sometimes also referred to in the art as EG cells or embryonic germ cells, when treated with appropriate factors form pluripotent ES cells from which embryoid bodies can be derived; see, e.g., US Patent US-A-5,670,372; Shamblott et al., supra.

[0031] The terms "polynucleotide" and "nucleic acid molecule" refer to a polymer of nucleotides of any length. Included are genes and gene fragments, mRNA, tRNA, rRNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA and RNA, nucleic acid probes, and primers. As used in this disclosure, the term polynucleotides refer interchangeably to double- and single-stranded molecules. Unless otherwise specified or required, any embodiment of the invention that is a polynucleotide encompasses both a double-stranded form, and each of the two complementary single-stranded forms known or predicted to make up the double-stranded form. Included are nucleic acid analogs such as phosphoramidates and thiophosphoramidates.

[0032] A cell is said to be "genetically altered", "transfected" or "genetically transformed" when a polynucleotide has been transferred into the cell by any suitable means of artificial manipulation, or where the cell is a progeny of the originally altered cell that has inherited the polynucleotide. The polynucleotide will often comprise a transcribable sequence encoding a protein of interest, which enables the cell to express the protein at an elevated level. The genetic alteration is said to be "inheritable" if progeny of the altered cell have the same alteration.

[0033] A "regulatory sequence" or "control sequence" is a nucleotide sequence involved in an interaction of molecules that contributes to the functional regulation of a polynucleotide, such as replication, duplication, transcription, splicing, polyadenylation, translation, or degradation of the polynucleotide. Transcriptional control elements include promoters, enhancers, and repressors.

[0034] Particular gene sequences referred to as promoters, like the " α MHC" or "collagen" promoter, are polynucleotide sequences derived from the gene referred to that promote transcription of an operatively linked gene expression product. It is recognized that various portions of the upstream and intron untranslated gene sequence may in some instances contribute to promoter activity, and that all or any subset of these portions may be present in the genetically engineered

construct referred to. The promoter may be based on the gene sequence of any species having the gene, unless explicitly restricted, and may incorporate any additions, substitutions or deletions desirable, as long as the ability to promote transcription in the target tissue. Genetic constructs designed for treatment of humans typically comprise a segment that is at least 90 % identical to a promoter sequence of a human gene. A particular sequence can be tested for activity and specificity, for example, by operatively linking to a reporter gene; see Figure 1. -

[0035] According to the present invention, the term "cell- and/or development-dependent promoter" is intended to mean a promoter which displays its promoter activity only in particular cell types and/or only in particular stages of cellular development, both in cell cultures (embryoid bodies) and in transgenic non-human mammals derived from the ES cells according to the invention. In addition, any other known cell-specific promoter can be employed, e.g. for nerve cells, heart cells, neurons, glia cells, hematopoietic cells, endothelial cells, smooth muscle cells, skeletal muscle cells, cartilage cells, fibroblasts and epithelial cells.

[0036] Genetic elements are said to be "operatively linked" if they are in a structural relationship permitting them to operate in a manner according to their expected function. For instance, if a promoter helps to initiate transcription of the coding sequence, the coding sequence can be referred to as operatively linked to (or under control of) the promoter. There may be an intervening sequence between the promoter and coding region as long as this functional relationship is maintained.

[0037] In the context of encoding sequences, promoters and other genetic elements, the term "heterologous" indicates that the element is derived from a genotypically distinct entity from that of the rest of the entity to which it is being compared. For example, a promoter or gene introduced by genetic engineering techniques into an animal of a different species is said to be a heterologous polynucleotide. An "endogenous" genetic element is an element that is in the same place in the chromosome where it occurs in nature, although other elements may be artificially introduced into a neighboring position.

[0038] The terms "polypeptide", "peptide" and "protein" are used interchangeably in this disclosure to refer to polymers of amino acids of any length. The polymer may comprise modified amino acids, it may be linear or branched, and it may be interrupted by non-amino acids.

[0039] If not stated otherwise, the terms "compound", "substance" and "(chemical) composition" are used interchangeably herein and include, but are not limited to therapeutic agents (or potential therapeutic agents), agents of known toxicities such as neurotoxins, hepatic toxins, toxins of hematopoietic cells, myotoxins, carcinogens, teratogens, or toxins to one or more reproductive organs. The chemical compositions can further be agricultural chemicals, such as pesticides, fungicides, nematocides, and fertilizers, cosmetics, including so-called "cosmeceuticals", industrial wastes or by-products, or environmental contaminants. They can also be animal therapeutics or potential animal therapeutics.

[0040] Industrial products that can be tested with the methods of the present invention include bleaches, toilet, blocks, washing-up liquids, soap powders and liquids, fabric conditioners, window, oven, floor, bathroom, kitchen and carpet cleaners, dishwasher detergents and rinse aids, water-softening agents, descalers, stain removers, polishes, oil products, paints, paint removers, glues, solvents, varnishes, air fresheners, moth balls and insecticides.

[0041] New ingredients for household products are constantly being developed and need to be tested. For example, in recent years new enzymes (to digest stains) and "optical brighteners" (which make washing appear whiter) have been developed for use in washing powders and liquids. New surfactants (which cut through grease to remove ingrained dirt) and chemical "builders" (which act as water softeners and enable surfactants to work more effectively) have been developed for use in washing powders and liquids, washing-up liquids and various cleaning agents. But also medical materials have to be tested, for example dental materials such as new filling polymers, metal alloys, and bioactive ceramic. Furthermore, chemical compositions of any part of a device, such as catheters, electrodes, adhesives, paste, gel or cream may be tested with the method of the present invention in different concentrations and with different ingredients and impurities present.

[0042] As used herein, "molecular profile" or "profile" of a chemical composition or compound refers to a pattern of alterations in gene or protein expression, or both, in an ES cell, embryoid body, tissue, etc. contacted by the chemical composition compared to a like cell, embryoid body or tissue in contact only with culture medium.

Detailed description

[0043] Stem cells of various kinds have become an extremely attractive modality in regenerative medicine. They can be proliferated in culture, and then differentiated in vitro or in situ into the cell types needed. This plasticity makes them ideal models for toxicity testing as well as investigation of pharmaceuticals such as tissue-specific promoting factors. Particularly, embryoid bodies which consist of different cell types of the three germ layers that interact with each other provide a highly sensitive test system. The ability of the stem cells to differentiate into the different cell types in the presence of a test substance may depend on the ability of the substance to promote differentiation and/or the toxicity of said substance.

[0044] The method of monitoring cell differentiation in accordance with the present invention comprises:

- transfecting cells capable of differentiating into at least one particular cell type with at least one recombinant nucleic acid molecule comprising a reporter gene encoding a product that is secreted upon cell differentiation;
- introducing the cells into a non-human animal or culturing the cells under conditions allowing differentiation of the cells; and
- determining the amount or activity of the reporter gene product either within a body fluid of said transgenic non-human animal or the cell culture medium.

[0045] The present invention is based on the use of a reporter gene that is secreted. Surprisingly, it was found that secreted reporter molecules have certain advantages over the use of, for example, a fluorescent reporter like green fluorescent protein (GFP) and its derivatives. For example, Liu et al. (Biochem. Biophys. Res. Comm. 260 (1999) 712-717) observed toxic effects when using a GFP reporter. Such toxic effects can be avoided or at least minimized if a secreted reporter molecule is used, simply by exchanging the culturing medium on a regular basis and thereby preventing toxic concentration of the respective reporter molecule building up.

[0046] Also, a preferred method for the differentiation of cells is to grow them as embryoid bodies (EBs), which shows a high autofluorescence rate even when the cells were lysed. This background can render the use of fluorescent reporter genes for the monitoring of cell differentiation quite inefficient.

[0047] Other routinely used reporter molecules like, for example, beta-galactosidase or luciferase require the cells to be tested in a certain assay buffer which means that the cells have to be destroyed to determine enzyme activity. The system according to the invention avoids this by employing a secreted reporter molecule so that assaying the culture medium of the differentiating cells or the body fluid of an animal containing said cells is sufficient to monitor the reporter activity and thereby the differentiation.

[0048] This means, as shown in Example 3, that with the reporter system of the invention on the one hand it is possible to quantify stem cell-derived cell types such as cardiomyocytes and on the other hand or in addition to monitor the differentiation process of the individual stem cell. Accordingly, monitoring cell differentiation in accordance with the present invention includes both, i.e. monitoring cell differentiation by quantifying the differentiated cells and/or following the differentiation process of one or more of the corresponding undifferentiated cells, for example stem cells.

[0049] For the transfection of the nucleic acid molecule encoding the reporter protein any standard method known to the person skilled in the art can be employed. Any suitable expression vector for this purpose can be used. Suitable viral vector systems for producing stem cells altered according to this invention can be prepared using commercially available virus components. The introduction of the vector construct or constructs into the cells occurs in a known manner, e.g. by transfection or transduction with the help of viral vectors. Transfection of vector plasmids into cells can be accomplished by, e.g., electroporation or lipofection, i.e. using lipid/DNA complexes. Exemplary is the formulation Lipofectamine 2000(TM), available from Gibco/Life Technologies. Another exemplary reagent is FuGENE(TM) 6 Transfection Reagent, a blend of lipids in non-liposomal form and other compounds in 80 % ethanol, obtainable from Roche Diagnostics Corporation. Viral vectors comprising effector genes are generally described in the publications referenced in the last section.

[0050] The cells to be transfected have to be able to differentiate into at least one particular cell type. This will be the case for the precursor cell for the desired cell type. Precursor cells include, but are not limited to, for example, the human neuronal precursor cell line NTERA-2 cl.D1. (Leypoldt et al., J. Neurochem. 76 (2001), 806-814), the human retinal precursor cell line KGLDMSM (Ezeonu et al., DNA Cell Biol. 19 (2000), 527-537), a human leukemic cell line, PER-117, bearing the markers of a T-cell precursor phenotype (Kees, Blood 72 (1988), 1524-1529) or HL60, a promyelocytic leukemia cell line that differentiates to mature neutrophils (Fontana, Proc. Natl. Acad. Sci. USA 77 (1980), 3664-3668).

[0051] Since these precursor cell lines have only a limited range of developmental capacity it is preferred that multipotent or pluripotent cells are used. This is the case when said cells are or are derived from stem cells or primordial germ cells, which are preferred in the embodiments of the present invention.

[0052] Any part of the description relating to human embryonic stem cells which could be prepared exclusively by a method that necessarily involves the destruction of human embryos is not part of the invention. References thereto are solely for descriptive purposes.

[0053] The invention can be practiced using stem cells of any vertebrate species. Included are stem cells from humans as well as non-human primates, domestic animals, livestock, and other non-human mammals. Preferred sources for stem cells are rodents, in particular mice and rats. Amongst the stem cells suitable for use in this invention are primate pluripotent stem cells derived from tissue formed after gestation, such as a blastocyst, or fetal or embryonic tissue taken any time during gestation. Non-limiting examples are established lines of embryonic stem cells. The invention is also applicable to adult stem cells, for example multipotent adult progenitor cells (MAPCs); see, e.g., Reyes and Verfaillie, Ann. N Y Acad. Sci. 938 (2001), 231-235 and Weissman and Anderson, Annu. Rev. Cell Dev. Biol. 17 (2001), 387-403. It is also referred to the literature of Anderson et al., Nat. Med. 7 (2001), 393-395, and Prockop, Science 276 (1997), 71-74, wherein the extraction and culture of adult stem cells is described.

[0054] Media for isolating and propagating stem cells can have any of several different formulas, as long as the cells

obtained have the desired characteristics, and can be propagated further. Suitable sources include Iscove's modified Dulbecco's medium (IMDM), Gibco, #12440-053; Dulbecco's modified Eagles medium (DMEM), Gibco #11965-092; Knockout Dulbecco's modified Eagles medium (KO DMEM), Gibco #10829-018; 200 mM L-glutamine, Gibco # 15039-027; non-essential amino acid solution, Gibco 11140-050; [beta]-mercaptoethanol, Sigma # M7522; human recombinant basic fibroblast growth factor (bFGF), Gibco # 13256-029. Exemplary serum-containing ES medium and conditions for culturing stem cells are known, and can be optimized appropriately according to the cell type. Media and culture techniques for particular cell types referred to in the previous section are provided in the references cited herein.

[0055] Because of their wide range of developmental capacity said stem cells are embryonic stem (ES) cells in a particularly preferred embodiment of this invention.

[0056] As mentioned before, several sources for ES cells are at the disposal of the skilled person of which human stem cells are preferred for most of the embodiments of the present invention. Human embryonic stem cells and their use for preparing different cell and tissue types are also described in *Reprod. Biomed. Online* 4 (2002), 58-63. Embryonic stem cells can be isolated from blastocysts of members of the primate species (Thomson et al., *Proc. Natl. Acad. Sci. USA* 92 (1995), 7844). Human embryonic germ (EG) cells can be prepared from primordial germ cells present in human fetal material taken about 8-11 weeks after the last menstrual period. Suitable preparation methods are described in Shamblo et al., *Proc. Natl. Acad. Sci. USA* 95 (1998), 13726. Methods for making cells that resemble embryonic stem cells or embryonic germ cells in morphology and pluripotency derived from primordial germ cells isolated from human embryonic tissue, such as from the gonadal ridges of human embryo, are described in US patent US-A-6,245,566.

[0057] Recently, it has been reported that exfoliated human deciduous tooth, a comparably very accessible tissue, contains multipotent stem cells that were identified to be a population of highly proliferative, clonogenic cells capable of differentiating into a variety of cell types including neural cells, adipocytes, and odontoblasts; see Miura et al., *Proc. Natl. Acad. Sci. USA* 100 (2003), 5807-5812. After in vivo transplantation, those cells were found to be able to induce bone formation, generate dentin, and survive in mouse brain along with the expression of neural markers. Furthermore, multilineage potential of homozygous stem cells derived from metaphase II oocytes has been described by Lin et al. in *Stem Cells* 21 (2003), 152-161. Various sources of precursor cells in postnatal muscles and the factors that may enhance stem cell participation in the formation of new skeletal and cardiac muscles in vivo are reviewed in Grounds et al. *J. Histochem. Cytochem.* 50 (2002), 589-610. Purification of rare hematopoietic stem cell(s) (HSC) to homogeneity that home to bone marrow is described in US patent application US2003/0032185. These adult bone marrow cells are described to have tremendous differentiative capacity as they can also differentiate into epithelial cells of the liver, lung, gastro-intestinal tract, and skin. This finding may contribute to clinical treatment of genetic diseases or tissue repair. Furthermore, techniques such as nuclear transfer for embryo reconstruction may be employed, wherein diploid donor nuclei are transplanted into enucleated MII oocytes. This technology along with other procedures that aid in the establishment of customized embryonic stem (ES) cell lines that are genetically identical to those of the recipient have been reviewed by Colman and Kind, *Trends Biotechnol.* 18 (2000), 192-196.

[0058] The field of stem cell technology is being reviewed by Kiessling and Anderson, Harvard Medical School, in *Human Embryonic Stem Cells: An Introduction to the Science and Therapeutic Potential*; (2003) Jones and Bartlett Publishers; ISBN: 076372341X.

[0059] In order to avoid the use of, for example, human embryos as the donor for stem cells, it may be possible to employ transgenic non-human animals, in particular mammals as source for embryonic stem cells. For example, compositions and methods for making transgenic swines to be used as xenograft donors are described in US patent US-A-5,523,226. Likewise, WO97/12035 describes methods of producing transgenic animals for xenotransplantation. Furthermore, immunologically compatible animal tissue, suitable for xenotransplantation into human patients, is described in WO01/88096. Methods for making embryonic germ cells from porcine are described for example in US patent US-A-6,545,199. Cells immunologically compatible with humans can also be employed for purposes of the present invention.

[0060] Stem cells can be propagated continuously in culture, using a combination of culture conditions that promote proliferation without promoting differentiation. Traditionally, stem cells are cultured on a layer of feeder cells, typically fibroblast type cells, often derived from embryonic or fetal tissue. The cell lines are plated to near confluence, usually irradiated to prevent proliferation, and then used to support when cultured in a medium conditioned by certain cells (e.g. Koopman and Cotton, *Exp. Cell Res.* 154 (1984), 233-242; Smith and Hooper, *Devel. Biol.* 121 (1987), 1-91), or by the exogenous addition of leukemia inhibitory factor (LIF). Such cells can be grown relatively indefinitely using the appropriate culture conditions without differentiation.

[0061] In the absence of feeder cells, exogenous leukemia inhibitory factor (LIF), or conditioned medium, ES or EG cells spontaneously differentiate into a wide variety of cell types, including cells found in each of the endoderm, mesoderm, and ectoderm germ layers. With the appropriate combinations of growth and differentiation factors, however, cell differentiation can be controlled. For example, mouse ES and EG cells can generate cells of the hematopoietic lineage in vitro (Keller et al., *Mol. Cell Biol.* 13 (1993), 473-486; Palacios et al., *Proc. Natl. Acad. Sci. USA* 92 (1995), 7530-7534; Rich, *Blood* 86 (1995), 463-472). Additionally, mouse ES cells have been used to generate in vitro cultures of neurons (Bain et al., *Developmental Biology* 168 (1995), 342-357; Fraichard et al., *J. Cell Science* 108 (1995), 3161-3188),

cardiomyocytes (heart muscle cells) (Klug et al., *Am. J. Physiol.* 269 (1995), H1913-H1921), skeletal muscle cells (Rohwedel et al., *Dev. Biol.* 164 (1994), 87-101), vascular cells (Wang et al., *Development* 114 (1992), 303-316). US patent US-A-5,773,255 relates to glucose-responsive insulin-secreting pancreatic beta cell lines, US patent US-A-5,789,246 relates to hepatocyte precursor cells. Hepatic differentiation of murine embryonic stem cells is also described in Jones et al., *Exp. Cell Res.* 272 (2002), 15-22.

[0062] Other progenitors of interest include, but are not limited to chondrocytes, osteoblasts, retinal pigment epithelial cells, fibroblasts, skin cells such as keratinocytes, dendritic cells, hair follicle cells, renal duct epithelial cells, smooth and skeletal muscle cells, testicular progenitors, and vascular endothelial cells.

[0063] In certain embodiments of the invention, differentiation is promoted by withdrawing one or more medium component(s) that promote(s) growth of undifferentiated cells, or act(s) as an inhibitor of differentiation. Examples of such components include certain growth factors, mitogens, leukocyte inhibitory factor (LIF), and basic fibroblast growth factor (bFGF). Differentiation may also be promoted by adding a medium component that promotes differentiation towards the desired cell lineage, or inhibits the growth of cells with undesired characteristics.

[0064] In a preferred embodiment of the present invention, said reporter gene in the recombinant nucleic acid molecule described above is operably linked to at least one cell type-specific regulatory sequence. This embodiment has the advantage of providing not only a monitoring system for differentiation per se but also allows observing the differentiation into a certain cell type. The regulatory sequence will drive the expression of the reporter molecule only in those cells that acquire the desired cell type by differentiation. Usually, said regulatory sequence comprises such promoter and/or enhancer elements. In addition, or alternatively, a second reporter gene can be used which is under the control of said cell type-specific regulatory sequence. The second reporter gene may be the same as used for the differentiation-dependent expression or different, including conventional reporter genes such as green fluorescent protein (GFP). Furthermore, the second reporter gene may be present in the mentioned recombinant nucleic acid molecule or on a different vector construct, the latter option requiring co-transfection of both molecules into the cells.

[0065] In a further embodiment, the differentiated cells containing the recombinant nucleic acid molecule of the present invention, and optionally further foreign DNA such as vector constructs described above, are enriched and separated from non-differentiated cells and/or from cells of non-desired cell types. Thus, in accordance with this invention, populations of differentiated cells are depleted of relatively undifferentiated cells and/or of cells of undesired cell types by using a selection system that is lethal to the undesired cells and cell types. This can be achieved, for example, by expressing a selectable marker gene under the control of a regulatory sequence that causes the gene to be preferentially expressed in the desired cell type and/or at a certain stage of development, which renders cells of a specific cell type resistant to a lethal effect of an external agent. To accomplish this, the cells are genetically altered with a recombinant nucleic acid molecule comprising the selectable marker gene before the process used to differentiate the cells into the desired lineage. The selection system may be present in the recombinant nucleic acid molecule of the present invention or on a different vector construct which is used for co-transfection.

[0066] The cell types which the differentiation can be directed to, include connecting fibroblasts, stromal cells, endothelial cells, glia cells, neural cells, neuronal cells, hematopoietic cells, smooth muscle cells, skeletal muscle cells, epithelial cells, and cardiac cells. To monitor differentiation into these particular cell types, regulatory sequences have to be operatively linked to the reporter gene sequence that confers an expression of the reporter which is specific for said cell types.

[0067] In a preferred embodiment of the method according to the invention, said promoter or enhancer is selected from the group consisting of α MHC, MLC2V, VE-cadherin, Tie-2, Fik-1, Flt-1, GFAP, alpha-1 tubulin and collagen 2 promoter or enhancer. Whereas the pro-alpha (II) collagen chain (collagen 2) promoter/enhancer (Zhou et al., *J. Cell Sci.* 108 (1995), 3677-3684) is specific for chondrocytes, the expression in endothelial cells can be driven by the VE-cad promoter (Gory et al., *Blood* 93 (1999), 184-192), the Flt-1 promoter (Quinn et al., *Biochem. Biophys. Res. Commun.* 276 (2000), 1089-1099), the Tie-2 (Schlaeger et al., *Proc. Natl. Acad. Sci. USA* 94 (1997), 3058-3063) and the Fik-1 promoter/enhancer (Kappel et al., *Blood* 93 (1999), 4284-4292), respectively. The alpha-1 tubulin promoter (Gloster et al., *J. Neurosci.* 14 (1994), 7319-7330) and the glial fibrillary acidic protein (GFAP) promoter (Besnard et al., *J. Biol. Chem.* 266 (1991), 18877-18883) are specific for neural cells. The smooth muscle heavy chain (SMHC) minimal promoter is specific for smooth muscles (Kallmeier et al., *J. Biol. Chem.* 270 (1995), 30949-30957). An HSV-1 vector containing the rat tyrosine hydroxylase promoter for use in both long-term and cell type-specific expression in the midbrain is described by Song et al., in *J. Neurochem.* 68 (1997), 792-803. Cardiac-specific promoters such as alpha-myosin heavy chain promoter (α MHC) and the myosin light chain-2v (MLC2v) promoter, the latter being specific for ventricular heart muscles, are described further below.

[0068] Further examples for tissue-specific promoters are those which are active in hematopoietic cells, cartilage cells or epidermal cells as well as insulin-secreting β -cells.

[0069] "Tissue-specific" is to be subsumed under the term "cell-specific". Regulatory sequences of the above described cell types and other cell type-specific promoters can be obtained from the literature; see, e.g., "medline" and NCBI.

[0070] Cardiovascular diseases are still among the most frequent causes of death in the western industrial countries.

Only through intensive basic research in this field, the pathophysiological causes can be found, and new therapeutic approaches can be devised, and toxicological changes described. For studying the pathogenesis of cardiovascular diseases and for testing new pharmacological and toxicological substances, models are needed which, on one hand, can be transferred to humans and, on the other hand, can replace the tedious and cost-intensive animal models. Still
5 in the year 1991, over 2 million animals have been employed for animal experiments in the federal states of the former Western Germany alone.

[0071] One starting point of pharmacological and toxicological research which has recently grown more and more important is heart differentiation. From the stereotypically proceeding heart cell development, conclusions can be drawn to pathological and toxicological changes of cardiomyocytes. Thus, for example, it is known that the receptor state and the intracellular signal cascades are disturbed in cardiac hypertrophy (Yamazaki et al., *J. Mol. Cell Cardiol.* 27 (1995), 133-140) and heart insufficiency (Johnson et al., *Biochem. Pharmacol.* 45 (1993), 2365-2372). These pathologically altered cardiomyocytes are in part again similar to heart cells of early differentiation stages. Thus, besides toxicological tests assays for the identification and isolation of substances that are capable of promoting cardiac remodeling are needed, which can be used for therapeutic interventions in the treatment of patients with cardiac dysfunction characterized
15 by, for example, pathological hypertrophy and fibrosis.

[0072] However, the examinations necessary for elucidating the properties of heart cells in early differentiation stages are technically difficult to perform with live animals and, if they can be performed at all, it is only in very complicated studies: On day 12-13, at the earliest, it is possible to prepare cardiomyocytes from a murine embryo, but such cells no longer correspond to an early cardiac differentiation stage. A detailed analysis of receptor expression during various
20 differentiation stages requires a very high expense of animal material and is technically difficult to perform as set forth above. Similarly, the observation of the development of a relatively undifferentiated heart cell over several days or weeks is not possible with an animal model. In order to test the use of novel therapeutical agents, e.g., inotropic substances or antiarrhythmics or toxic substances, e.g., heavy metals or retinoids, an invasive monitoring of animals, e.g., swine, must be performed for weeks in animal experiments.

[0073] Now, it has been the object of the present invention to provide a cell-based assay which enables a simple characterization of the effects of compounds on cardiomyogenesis and allows for functional examinations rather than being based on reporter genes such as Lac-Z (Niwa et al., *Gene* 108 (1991), 193-199; Wobus et al., *J. Mol. Cell Cardiol.* 29 (1997), 1525-1539; Metzger et al., *Circ. Res.* 78 (1996), 547-552), as with prior methods, the expression of which genes can be detected only after cell fixation and by means of a specific substrate.
25

[0074] Surprisingly, it has been found that ES cells can be stably transfected with a DNA construct in which a gene encoding a secreted reporter protein is coupled with a cardiomyocyte-specific cell- and development-dependent promoter; see the examples and the vector sequence depicted in SEQ ID NO: 3. This construct is integrated in the native DNA and after the specific activation of intracellular signals, the promoter is activated and the reporter protein expressed and secreted into the medium. Thus, ES cells which activate a cell-specific transcription factor at a certain point of
30 differentiation could be recognized by determining the level of reporter protein or its activity in the cell culture medium.

[0075] The purpose of the method of the present invention as illustrated in the examples carries with it that the reporter molecule employed should preferably truly be secreted into the cell culture medium, or in case of a transgenic non-human animal, into the body fluid. Otherwise, if the once secreted reporter molecule would be recaptured from the medium and the body fluid, respectively, it would hardly be possible to quantify the differentiated cells, since the measured amount of activity or active protein in the cell culture supernatant or body fluid might not properly or at all correspond to the actual number of differentiated cells and/or the status of differentiation. Therefore, reporter molecules such as human alpha-galactosidase which, when correctly glycosylated, can be taken up by the cells via mannose-6 phosphate receptors, would probably at least in its native form not be a suitable reporter molecule for the purposes of the present invention. Nevertheless, this enzyme may be rendered suitable for the purposes of the present invention, e.g., by abolishing its
35 capability of being glycosylated, for example by means of corresponding mutations in the underlying DNA encoding the enzyme.

[0076] In a particularly preferred embodiment of the invention, said differentiating cell type are cardiomyocytes. For this embodiment, said cell type-specific regulatory sequence is preferably atrial- and/or ventricular-specific. Corresponding regulatory sequences, i.e. cardiac-specific promoters are described in the prior art; see also supra. For example, Nkx-2.5 specific for very early cardiomyocytes and mesodermal precursor cells, respectively (Lints et al., *Development* 119 (1993), 419-431); human-cardiac- α -actin specific for heart tissue, (Sartorelli et al., *Genes Dev.* 4 (1990), 1811-1822), and MLC-2V specific for ventricular heart muscle cells (O'Brien et al., *Proc. Natl. Acad. Sci. USA.* 90 (1993), 5157-5161; Lee et al., *Mol. Cell Biol.* 14 (1994), 1220-1229; Franz et al., *Circ. Res.* 73 (1993), 629-638 and WO96/16163). The cardiac-specific alpha-myosin heavy chain promoter is described in Palermo et al., *Cell Mol. Biol. Res.* 41 (1995), 501-519 and Gulick et al., *J. Biol. Chem.* 266 (1991), 9180-91855. The expression of the atrial-specific myosin heavy chain AMHCl and the establishment of anteroposterior polarity in the developing chicken heart is described in Yutzey et al., *Development* 120 (1994), 871-883.
40

[0077] Since the detection is aided by using a reporter molecule for which a robust, sensitive and specific assay exists,
45

a particularly preferred embodiment is the method according to the invention, wherein said reporter gene product is secreted alkaline phosphatase (SEAP), alpha-amylase or invertase.

[0078] SEAP is heat-resistant and not inhibited by L-homoarginine. Further advantages of this reporter molecule are its low toxicity and the fact that the protein levels that are secreted correspond directly to the amount of intracellular mRNA. Thus, the SEAP reporter assay provides a direct measurement for the cell type-specific expression and thereby the differentiation. It is also extremely sensitive: it is possible to detect 10^{-13} g SEAP protein (Yang et al., *Biotechniques* 23 (1997), 1110-1114). This makes it possible to detect differentiation into cell types that are rare.

[0079] The use of alpha-amylase as reporter molecule is described in, for example, WO98/49320. This reporter molecule is particularly attractive because the enzyme is extremely stable over a wide range of conditions. The measurement of alpha-amylase activity is simple, quantitative, sensitive, safe and inexpensive. It was also shown to be compatible with a SEAP reporter system (Schlatter et al., *Gene* 282 (2002), 19-31). The use of invertase as a marker protein is described for example in Mace et al., *Virology* 188 (1992), 869-874.

[0080] Reporter gene constructs comprising inter alia secreted alkaline phosphatase as the reporter molecule and which therefore can be used as a source for preparing vector constructs according to the present invention are described for example in WO00/34435 and Wang et al., *Gene* 279 (2001), 99-108, the latter describing murine SEAP. Detection of SEAP level can be performed as described in the examples and in the prior art; see, e.g., Bronstein et al., *Biotechniques* 17 (1994), 172-177; Yang et al. (1997) and Wang et al. (2001), supra. The use of human secreted alkaline phosphatase in an in vivo mouse reporter gene model to monitor ovarian tumor growth and response to therapeutics has been described in Nilsson et al., *Cancer Chemother. Pharmacol.* 49 (2002), 93-100. This model can be adapted to the embodiments of the present invention. Engineered secreted alkaline phosphatase reporter genes being capable of being expressed in a mammal for extended periods of time and detection of the alkaline phosphatase activity by measuring the protein levels or AP activity of a serum or tissue sample from a mammal containing the cell with the transgene, or measuring the media from a cultured cell containing the transgene are also described in WO02/095068. Reporter activity or protein amount, in particular SEAP activity, can be detected in any biological fluid such as breast milk, amniotic fluid, seminal plasma, serum and urine.

[0081] Since not all molecules that can be used as a reporter are secreted naturally, the nucleic acid molecule introduced into the cells can be genetically engineered to encode a protein that is excreted. Particularly preferred is the method described above, wherein said reporter gene product comprises a secretory leader sequence. Examples for secretory leader sequences are but are not limited to the adenovirus tripartite leader sequence (Chu et al., *Biotechniques* 5 (1995), 890-896), the immunoglobulin secretion signal (Schlatter et al., *Gene* 282 (2002), 19-31), the SUC2 signal sequence as well as the human interleukin 2 receptor alpha chain signal sequence (Kamiya et al., *Tohoku J. Exp. Med.* 180 (1996), 297-308).

[0082] In order to select those cells which contain the recombinant nucleic acid molecule according to the invention, and optionally other vector constructs such as those described hereinbefore, said recombinant nucleic acid molecules and vector constructs, respectively, preferably further comprise a selectable marker expressed by multi- or pluripotent cells. Selectable markers are known to the person skilled in the art and include, for example, nucleoside and aminoglycoside-antibiotic-resistance genes conferring resistance to, e.g., puromycin, neomycin or hygromycin. Further examples for resistance genes are dehydrofolate-reductase, which confers a resistance against aminopterin and methotrexate, as well as multi drug resistance genes, which confer a resistance against a number of antibiotics, e.g. against vinblastin, doxorubicin and actinomycin D; see, e.g., Blau et al., *Blood* 89 (1997), 146-154, which describes the use of the multiple drug resistance gene 1 (MDR1) gene as a dominant selectable marker.

[0083] In a particularly preferred embodiment of the present invention, said selectable marker confers resistance to puromycin. Puromycin is particularly suited for the fast elimination of non-cardiac cells in adherent culture of transgenic EBs. Furthermore, drug selection of cardiac cells can be implemented entirely in the suspension culture of transgenic EBs. Hence, it could also be shown that purified ES cell-derived cardiomyocytes survive much longer in culture than untreated counterparts. Moreover, the elimination of undifferentiated ES cells during drug selection process has itself been shown to have a clear positive effect on viability and longevity of such differentiated ES cell-derived cells as cardiomyocytes. In addition, it could be surprisingly shown that the release from surrounding non-differentiated cells induces proliferation of cardiomyocytes. Thus, the drug selection possesses both a purifying and multiplying effect; see, e.g., WO02/051987. Thus, the selection does not only provide the means for eliminating cells which can not be monitored since they do not carry the reporter gene, it also allows the elimination of cells that did not differentiate into the desired cell type, provided that the reporter gene and the selectable marker gene are driven by the same, cell type-specific regulatory sequence.

[0084] The method according to the invention, wherein said cells form cell aggregates or tissue-like aggregates derived from different ES cell types is a preferred embodiment, and particularly preferred are said cells forming embryoid bodies (EBs). As mentioned before, embryoid bodies represent a complex group of cells differentiating into different tissue. In one embodiment, the cells within an embryoid body are substantially synchronized for their differentiation. Accordingly, at known intervals, the majority of the synchronized cells differentiate into the three embryonic germ layers and further

differentiate into multiple tissue types, such as cartilage, bone, smooth and striated muscle, and neural tissue, including embryonic ganglia; see also Snodgrass et al., "Embryonic Stem Cells: Research and Clinical Potentials" in Smith and Sacher, eds. *Peripheral Blood Stem Cells* American Association of Blood Banks, Bethesda MD (1993). Thus, the cells within embryoid bodies provide a much closer model to the complexity of whole organisms than do traditional single cell or yeast assays, while still avoiding the cost and difficulties associated with the use of mice or rats and larger mammals. Moreover, the recent availability of human embryoid bodies improves the predictive abilities of the invention by providing an even closer vehicle for modeling toxicity and identification of drugs useful for the treatment of heart disorders in human organ systems, and in humans.

[0085] The embryoid body of the invention comprises a cell population, the majority of which being pluripotent cells capable of developing into different cellular lineages when cultured under appropriate conditions. It is preferred that the embryoid body comprises at least 51 % pluripotent cells derived from totipotent ES cells. More preferably, the embryoid body comprises at least 75 % pluripotent cells derived from totipotent ES cells. And still more preferably, the embryoid body comprises at least 95 % pluripotent cells derived from totipotent ES cells.

[0086] In its simplest form, the method of creating a molecular profile according to the present invention involves contacting embryoid bodies with a chemical composition of interest, and then determining the alterations in reporter activity or amount of reporter protein, or both, in the embryoid body exposed to the chemical composition (the "test embryoid body") compared to a embryoid body which was not exposed to the agent (a "control embryoid body").

[0087] Thus, the method of the present invention can be performed such that it allows self-assembly of the cells into the aggregates or tissue-like structures. The term "embryoid bodies" (EBs) is a term of art synonymous with "aggregate bodies". The terms refer to aggregates of differentiated and undifferentiated cells that appear when ES cells overgrow in monolayer cultures, or are maintained in suspension cultures. Embryoid bodies are a mixture of different cell types, typically from several germ layers, distinguishable by morphological criteria. WO02/051987 describes a protocol to obtain embryoid bodies. The manufacturing takes place preferably with the "hanging drop" method or by methylcellulose culture (Wobus et al., *Differentiation* 48 (1991), 172-182).

[0088] Alternatively to this, spinner flasks (stirring cultures) can be used as culture method. Therefore, the undifferentiated ES cells are introduced into stirring cultures and are mixed permanently according to an established procedure. Therefore, 10 million ES cells are introduced into 150 ml medium with 20 % FCS and are stirred constantly with the rate of 20 rpm, wherein the direction of the stirring motion is changed regularly. 24 hours after introduction of the ES cells an extra 100 ml medium with serum is added and thereupon 100-150 ml of the medium is exchanged every day (Wartenberg et al., *FASEB J.* 15 (2001), 995-1005). Under these culture conditions large amounts of ES cell-derived cells, i.e. cardiomyocytes, endothelial cells, neurons etc., depending on the composition of the medium, can be obtained. The cells are selected by means of the resistance gene either still within the stirring culture or after plating, respectively.

[0089] In a particularly preferred embodiment of the present invention, embryoid bodies are prepared according to a recently developed "mass culture" system employed in the appended examples and described in detail in international application WO2005/005621.

[0090] The embryoid bodies used to test the chemical composition can be of any vertebrate species. The choice of the particular species from which the embryoid body is derived will typically reflect a balance of several factors. First, depending on the purpose of the study, one or more species may be of particular interest. For example, human embryoid bodies will be of particular interest for use with compositions being tested as potential human therapeutics but also for toxicological tests for substances including industrial chemicals, while equine, feline, bovine, porcine, caprine, canine, or sheep embryoid bodies may be of more interest for a potential veterinary therapeutic. Embryoid bodies of other species commonly used in preclinical testing, such as guinea pigs, mice, rat, rabbits, pigs, and dogs, are also preferred. Typically, embryoid bodies of these species will be used for "first pass" screening, or where detailed information on toxicity in humans is not needed, or where a result in a murine or other one of these laboratory species has been correlated to a known toxicity or other effect in humans. Furthermore, with respect to human therapeutics, regulatory agencies generally require animal data before human trials can begin; it will generally be desirable to use embryoid bodies of species which will be used in the preclinical animal studies. The results of toxicity testing in the embryoid bodies can then guide the researcher on the degree and type of toxicity to anticipate during the animal trials. Certain animal species are known in the art to be better models of human toxicity of different types than are others, and species also differ in their ability to metabolize drugs; see, e.g., Williams, *Environ. Health Perspect.* 22 (1978), 133-138; Duncan, *Adv. Sci.* 23 (1967), 537-541. Thus, the particular species preferred for use in a particular preclinical toxicity study may vary according to the intended use of the drug candidate. For example, a species which provides a suitable model for a drug intended to affect the reproductive system may not be a suitable model for a drug intended to affect the nervous system. Criteria for selecting appropriate species for preclinical testing are well known in the art.

[0091] Once an embryoid body culture has been initiated, it can be contacted with a chemical composition. Conveniently, the chemical composition is in an aqueous solution, preferably in a solvent conventionally used in cell culture, for example DMSO, and is introduced to the culture medium; see also the examples. The introduction can be by any convenient means, but will usually be by means of a pipette, a micropipettor or a syringe. In some applications, such as

high throughput screening, the chemical compositions will be introduced by automated means, such as automated pipetting systems, which may be on robotic arms. Chemical compositions can also be introduced into the medium as in powder or solid forms, with or without pharmaceutical excipients, binders, and other materials commonly used in pharmaceutical compositions, or with other carriers which might be employed in the intended use. For example, chemical compositions intended for use as agricultural chemicals or as petrochemical agents can be introduced into the medium by themselves to test the toxicity of those chemicals or agents, or introduced in combination with other materials with which they might be used or which might be found in the environment, to determine if the combination of the chemicals or agents has a synergistic effect. Typically, the cultures will be shaken at least briefly after introduction of a chemical composition to ensure that the composition is dispersed throughout the medium.

[0092] The time at which a chemical composition is added to the culture is within the discretion of the practitioner and will vary with the particular study objective. Conveniently, the chemical composition will be added as soon as the embryoid body develops from the stem cells, permitting the determination of the alteration in protein or gene expression on the development of all the tissues of the embryoid body. It may be of interest, however, to focus the study on the effect of the composition on a particular tissue type. As previously noted, individual tissue, such as muscle, nervous, and hepatic tissue, are known to develop at specific times after the embryoid body has formed. Addition of the chemical composition can therefore be staged to occur at the time the tissue of interest commences developing, or at a chosen time after commencement of that development, in order to observe the effect on altering gene or protein expression in the tissue of interest.

[0093] Different amounts of a chemical composition will be used to contact an embryoid body depending on the amount of information known about the toxicity of that composition, the purposes of the study, the time available, and the resources of the practitioner. A chemical composition can be administered at just one concentration, particularly where other studies or past work or field experience with the compound have indicated that a particular concentration is the one which is most commonly found in the body. More commonly, the chemical composition will be added in different concentrations to cultures of embryoid bodies run in parallel, so that the effects of the concentration differences on gene or protein expression and, hence, the differences in toxicity of the composition at different concentrations, can be assessed. Typically, for example, the chemical composition will be added at a normal or medium concentration, and bracketed by twofold or fivefold increases and decreases in concentration, depending on the degree of precision desired.

[0094] Where the composition is one of unknown toxicity, a preliminary study is conveniently first performed to determine the concentration ranges at which the composition will be tested. A variety of procedures for determining concentration dosages are known in the art. One common procedure, for example, is to determine the dosage at which the agent is directly toxic. The practitioner then reduces the dose by one half and performs a dosing study, typically by administering the agent of interest at fivefold or twofold dilutions of concentration to parallel cultures of cells of the type of interest. For environmental contaminants, the composition will usually also be tested at the concentration at which it is found in the environment. For agricultural chemicals, such as pesticides which leave residues on foodstuffs, the agent will usually be tested at the concentration at which the residue is found, although it will likely be tested at other concentrations as well. Thus, the dilution of test compounds can be done by making in separated tubes a series of dilution of 50 or 100 fold concentrated compounds in DMSO. One or two μ l of each dilution are distributed in each well before cell suspension distribution. Particularly preferred are stock and dilution series as described for retinoic acid in Example 3.

[0095] The above considerations with respect to contacting the compounds with the EBs, contacting time, etc., also apply to the assays of the invention performed on, e.g., ES cells, tissue and non-human animals, if applicable.

[0096] The present invention also relates to reporter gene constructs for monitoring cell differentiation comprising the recombinant nucleic acid molecule defined previously as well as to cells capable of differentiating into at least one particular cell type, that contain said reporter gene construct, or are obtainable by the methods described herein. Likewise, cell aggregates, tissue, organs, implants or transplants comprising said reporter gene construct, obtainable by the methods described herein or constituted from said cells, cell aggregates, tissue, organs, implants or transplants are subject of the invention.

[0097] In a still further embodiment, the present invention relates to a transgenic non-human animal which can be generated from the mentioned ES cells and ES cell-derived cell types and cell aggregates; see supra. A method for the production of a transgenic non-human animal, which is encompassed by the present invention, for example transgenic mouse, comprises introduction of a reporter gene as described above into a germ cell, an embryonic cell, stem cell or an egg or a cell derived therefrom. The non-human animal can be used in accordance with a screening method of the invention described herein. Production of transgenic embryos and screening of those can be performed, e.g., as described by A. L. Joyner Ed., *Gene Targeting, A Practical Approach* (1993), Oxford University Press. A general method for making transgenic non-human animals is described in the art, see for example WO94/24274. For making transgenic non-human organisms (which include homologously targeted non-human animals), embryonal stem cells (ES cells) are preferred. Murine ES cells, such as AB-1 line grown on mitotically inactive SNL76/7 cell feeder layers (McMahon and Bradley, *Cell* 62 (1990), 1073-1085) essentially as described (Robertson, in *Teratocarcinomas and Embryonic Stem Cells: A Practical Approach*. E. J. Robertson, ed. (Oxford: IRL Press) (1987), 71-112) may be used for homologous gene targeting. Other

suitable ES cell lines include, but are not limited to the E14 line (Hooper et al., Nature 326 (1987), 292-295), the D3 line (Doetschman et al., J. Embryol. Exp. Morph. 87 (1985), 27-45), the CCE line (Robertson et al., Nature 323 (1986), 445-448), the AK-7 line (Zhuang et al., Cell 77 (1994), 875-884) and others; see also supra. The success of generating a mouse line from ES cells bearing a specific targeted mutation depends on the pluripotency of the ES cells (i.e. their ability, once injected into a host developing embryo, such as a blastocyst or morula, to participate in embryogenesis and contribute to the germ cells of the resulting animal). The blastocysts containing the injected ES cells are allowed to develop in the uteri of pseudopregnant non-human females and are born as chimeric mice. The resultant transgenic mice are backcrossed and screened for the presence of the correctly targeted transgene(s) by PCR or Southern blot analysis on tail biopsy DNA of offspring so as to identify transgenic mice for the reporter locus/loci. For example, transient expression of a recombinase gene directly introduced into fertilized eggs by pronuclear injection provides a fast and efficient method for generating mutant mice with desired deletions or translocations in target genes. Efficient removal of loxP-flanked DNA sequences in a gene-targeted locus by transient expression of Cre recombinase in fertilized eggs is described by Sunaga et al., Mol. Reprod. Dev. 46 (1997), 109-113.

[0098] Methods for producing transgenic flies, such as *Drosophila melanogaster* are also described in the art, see for example US-A-4,670,388, Brand and Perrimon, Development 118 (1993), 401-415; and Phelps and Brand, Methods 14 (1998), 367-379. Transgenic worms such as *C. elegans* can be generated as described in Mello et al., EMBO J. 10 (1991), 3959-3970, Plasterk, Methods Cell. Biol. 48 (1995), 59-80.

[0099] All of the embodiments described above can not only be used to monitor cell differentiation and optimize culturing conditions using modulators in their pure forms but the effective agent(s) might also be contained in a composition. Hence, compositions of matter comprising any one of those recombinant nucleic acid molecules, cells, cell aggregates, or tissue of the present invention as described herein are encompassed in the scope of the present invention. As described herein, those compositions and methods of the invention can be used for a variety of purposes, for example for analyzing early steps of tissue formation during embryonic development or the influence of factors and compounds on this process.

[0100] In a particularly preferred embodiment, the present invention relates to arrays and chips comprising a solid support and attached thereto or suspended thereon cells, cell aggregates or tissue obtained by the method of the present invention or being in the differentiation process. Such arrays generally consist of a substrate of glass, plastic or silicon on which the test cells aggregates or tissue are deposited in a particular pattern. Depending on the type of array, these might additionally be covered by a conductor, e.g., gold, platinum, indium-tin-oxide, iridium, etc., which allows a direct measurement by employing the conductivity of cells. The use of such planar microelectrode arrays for cultured cells and cell aggregates as biosensors is of particular interest.

[0101] Furthermore, the invention relates to an apparatus for analyzing said array, which will be able to measure the particular read-out of the assay employed, e.g., SEAP reaction product, in a quantitative manner and assign the results to the position on the array.

[0102] The system for monitoring cell differentiation according to the present invention can also be employed to identify and characterize substances that modify the differentiation process. Populations of differentiated cells and tissue suitable for human administration have to be identified after the differentiation process to avoid administering undifferentiated cells with high tumorigenic potential or cells differentiated into cells that are not needed for the particular therapeutic purpose. The positive identification of cells differentiated into a certain cell type allows also the optimization of culturing conditions that is necessary to obtain the relatively high numbers of differentiated cells needed for therapeutic purposes. Thus, there is a need to identify conditions for culturing ES cells that drive their differentiation into the desired direction.

[0103] Accordingly, a preferred embodiment of the invention is a method of obtaining and/or profiling a modulator of cell differentiation comprising:

- contacting a test sample comprising a cell, cell aggregate, tissue or organ or a non-human animal as defined above with a test substance; and
- determining the effect of the test substance on the amount of the reporter gene product or activity compared to a control sample or animal.

[0104] In particular, the methods of the invention can be used for toxicological, embryotoxic, mutagenic, and/or teratogenic in vitro tests; see supra. Another important aspect of the present invention is therefore a method of determining toxicity, preferably teratogenicity, embryotoxicity, chronic or acute toxicity of a compound comprising the steps of the methods described herein, wherein a reduced or enhanced level or activity of said reporter gene product is indicative for the toxicity of the compound.

[0105] The assays may be simple "yes/no" assays to determine whether there is a change in expression of the secreted reporter protein by detecting reporter, e.g., enzyme activity or the amount of reporter protein. The assay may be made quantitative by comparing the amount of activity and/or amount of reporter in a test sample with the levels of activity and/or amount in a standard sample. As described in the examples, the test compound or a plurality of test compounds

are subjected to the test cell, preferably an embryoid body in different concentrations or dilution series, preferably at doses that correspond to physiological levels of the corresponding type of test compounds; see also Example 3. It is thus also possible to easily generate compound profiles in purpose similar to those described in WO00/34525. For example, two or more assays may be used, wherein for each assay the test cells or, e.g., embryoid bodies comprise recombinant DNA molecules with different cell- and/or development-specific promoters operably linked to the same or different reporters, preferably wherein each reporter is a secreted protein, e.g., enzyme, most preferably wherein one or each reporter is SEAP. Those assays can be performed in parallel or subsequently; or the results of one assay may be compared with the results of a corresponding assay performed elsewhere. Likewise, it is envisaged to provide and use cells which comprise two of the mentioned recombinant molecules but with different promoters and reporters as mentioned above. Thus, a molecular profile of a test chemical composition can be established by detecting the alterations in reporter gene activity or amount of reporter protein in, for example, embryoid bodies contacted by the test chemical composition as described in previous sections. Once the molecular profile of the test composition is determined, it can be compared to that of a chemical composition with predetermined toxicities or, preferably, to a library of molecular profiles of chemical compositions with predetermined toxicities. The outcome of such comparison provides information for one to predict the likelihood of whether the test composition is toxic, what type of toxicity, and how toxic it would be as compared to the other known toxic compositions.

[0106] For the purpose of practicing the invention, the predictions of toxicity of the test composition based on its molecular profiles in ES cells, tissue, etc., preferably EB cells does not have to be 100 % accurate. To have a major positive impact on the efficiency and costs of drug development, one only has to modestly increase the probability that the less toxic and thus more successful drug candidates are, for example, on the top half of a prioritized list of new drug leads.

[0107] Furthermore, in Example 3 it has been demonstrated that the concentration-dependent effect of the test compound on the reporter molecule activity in culture supernatants is consistent with the concentration-dependent inhibition of the generation of the differentiated cell type by the test compound. Therefore, it is also possible to compare a compound profile generated with a method of the present invention with a compound profile provided by different means, for example, if both profiles quantify the in vitro differentiated cells.

[0108] Since the cells and tissue obtained in accordance with the present invention more closely resemble the in vivo situation compared to conventional cell-based assays, the results obtained by the assays of the present invention are expected to correlate to in vivo teratogenicity or embryotoxicity of the tested compounds as well. The simple read-out of the reporter molecule assay is easier measured and interpreted than determining the influence of a substance by monitoring the embryonic and post-natal development of a test animal in all aspects and in different stages of development. This requires a number of animals to be sacrificed at different ages, whereas by employing the reporter molecule secreted in a developmental-specific manner samples of body fluids from the animal can be obtained repeatedly and allowing the monitoring over an extended time period up to the life-time of the animal. This also reduces the variability of test results.

[0109] Several test substances can be combined and either added simultaneously or sequentially to gain information about possible enhancing or quenching effects. Thus, a further aspect of the invention relates to the method described previously, wherein said contacting step further includes contacting said test sample or animal with at least one second test substance in the presence of said first test substance. Two or more substances tested in combination will provide information about their interaction in general.

[0110] A preferred embodiment of the methods according to the present invention involves adding a compound known to activate or inhibit the differentiation process in the culture medium or animal, particularly if this test substance is a therapeutic agent or a mixture thereof. This screening may be done, for example, either because the compound is known to have an effect on the differentiation of certain cell types and is tested to determine its potential for guiding the differentiation of other cell types, or because a compound designed to have effects elsewhere may have unintended side effects. The last aspect applies particularly to therapeutic agents.

[0111] Both aspects of drug screening can be adapted to compound library screening methods as well as screening industrial chemicals from the shelf. Thus, another embodiment of the invention encompasses the method described above, wherein preferably in a first screen said test substance is comprised in and subjected as a collection of test substances. Such a collection of test substances, usually a combinatorial compound library, can have a diversity of about 10^3 to about 10^5 and is successively reduced in running the method several times until the diversity has been reduced down to a desired factor, preferably down to one compound or particular class of compounds. Optionally the method of the present invention can be combined with other screening methods known in the art. Methods for the generation and use of peptidomimetic combinatorial libraries are described in the prior art, for example in Ostresh, *Methods in Enzymology* 267 (1996), 220-234 and Domer, *Bioorg. Med. Chem.* 4 (1996), 709-715. Drug discovery by dynamic combinatorial libraries is described, for example, in *Nat. Rev. Drug Discov.* 1 (2002), 26-36 and *Drug Discov. Today* 7 (2002), 117-125. Compounds identified using the method of the invention can be further evaluated in single experiments employing other methods of the present invention.

[0112] Compounds and candidate agents are obtained from a wide variety of sources including libraries of synthetic

or natural compounds, or as mentioned industrial chemicals; see supra. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides and oligopeptides. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced. For example, inhibition of tumor-induced angiogenesis and matrix-metalloproteinase expression in confrontation cultures of embryoid bodies and tumor spheroids by plant ingredients used in traditional Chinese medicine has been described by Wartenberg et al. in *Lab. Invest.* 83 (2003), 87-98.

[0113] A preferred embodiment of the screening method is performed on an array as provided by the invention.

[0114] The assay methods of the present invention can be in a conventional laboratory format or adapted for high throughput screening. The term "high throughput screening" (HTS) refers to an assay design that allows easy analysis of multiple samples simultaneously, and capacity for robotic manipulation. Another desired feature of high throughput assays is an assay design that is optimized to reduce reagent usage, or minimize the number of manipulations in order to achieve the analysis desired. Examples of assay formats include 96-well, 384-well or more-well plates, levitating droplets, and "lab on a chip" microchannel chips used for liquid handling experiments. It is well known by those in the art that as miniaturization of plastic molds and liquid handling devices are advanced, or as improved assay devices are designed, that greater numbers of samples may be performed using the design of the present invention. In the method of the invention, said one or more cells or tissue are preferably contained in a container, for example in a well of a microtiter plate, which may be a 24-, 96-, 384- or 1586-well plate. Alternatively, the cells can be introduced into a microfluidics device, such as those provided by Caliper (Newton, MA, USA). In another preferred embodiment, the method of the present invention comprises taking 3, 4, 5, 7, 10 or more measurements, optionally at different positions within the container.

[0115] The methods according to the invention can also be performed using cells that are genetically engineered to (over)express or inhibit the expression of a target gene. Examples for genetically altered stem cells are described in WO03/014326, which provides mammalian stem cells expressing the VEGF receptor VEGFR-1, or WO95/06409 disclosing human hematopoietic stem cells expressing recombinant DNA constructs encoding a recombinant molecule containing a signal transducing region and an antigenic specificity region. Alternatively to using already altered stem cells, said target gene can be transfected at the same time as the construct of the present invention conferring the expression of the secreted reporter molecule.

[0116] HTS, combinatorial library screening as well as conventional assay formats can also be employed to identify novel compounds which have an effect on differentiation. Novel as well as compounds previously known to modulate cell differentiation can be used to manufacture a drug for this purpose. Thus, a preferred embodiment of the present invention is a method of obtaining and manufacturing a drug which promotes or inhibits formation of specific cell types comprising the steps of the methods described above, wherein an enhanced or reduced level or activity of the reporter gene product is indicative for the drug.

[0117] Compounds of interest encompass numerous chemical classes, though typically they are organic molecules. Candidate agents comprise functional groups necessary for structural interaction with proteins, particularly hydrogen bonding, and typically include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups. The candidate agents often comprise cyclical carbon or heterocyclic structures and/or aromatic or polyaromatic structures substituted with one or more of the above functional groups. Candidate agents are also found among biomolecules including peptides, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs or combinations thereof.

[0118] Additionally, natural or synthetically produced libraries and compounds are readily modified through conventional chemical, physical and biochemical means, and may be used to produce combinatorial libraries. Known pharmacological agents may be subjected to directed or random chemical modifications, such as acylation, alkylation, esterification, amidification, etc. to produce structural analogs.

[0119] The compounds may also be included in a sample including fluids to which additional components have been added, for example components that affect the ionic strength, pH, total protein concentration, etc. In addition, the samples may be treated to achieve at least partial fractionation or concentration. Biological samples may be stored if care is taken to reduce degradation of the compound, e.g., under nitrogen, frozen, or a combination thereof. The volume of sample used is sufficient to allow for measurable detection, usually from about 0.1 μ l to 1 ml of a biological sample is sufficient.

[0120] Differentiation processes do not only play a major role in embryonic development but are also important for an adult organism since the continuous replacement of senescent or cells damaged by injury or disease is achieved by precursor cells differentiating into the cells needed. An important aspect of the present invention is thus a method of manufacturing an agent which supports wound healing and/or healing of damaged tissue comprising the steps described herein, wherein an enhanced level or activity of the reporter gene product is indicative for said agent.

[0121] Compounds identified, isolated and/or produced by the methods described above can also be used as lead compounds in drug discovery and preparation of drugs or prodrugs. This usually involves modifying the lead compound or a derivative thereof or an isolated compound as described hereinbefore such as modifying said substance to alter, eliminate and/or derivatize a portion thereof suspected causing toxicity, increasing bioavailability, solubility and/or half-

life. Accordingly, a preferred embodiment of the present invention encompasses the methods described previously and further modifying said substance to alter, eliminate and/or derivatize a portion thereof suspected causing toxicity, increasing bioavailability, solubility and/or half-life. Methods for clinical compound discovery comprise for example ultra-high-throughput screening (Sundberg, *Curr. Opin. Biotechnol.* 11 (2000), 47-53) for lead identification, and structure-based drug design (Verlinde and Hol, *Structure* 2 (1994), 577-587) and combinatorial chemistry (Salemme et al., *Structure* 15 (1997), 319-324) for lead optimization. The various steps recited above are generally known in the art. For example, computer programs for implementing these techniques are available, e.g., Rein, *Computer-Assisted Modeling of Receptor-Ligand Interactions* (Alan Liss, New York, 1989). Methods for the preparation of chemical derivatives and analogs are well known to those skilled in the art and are described in, for example, Beilstein, *Handbook of Organic Chemistry*, Springer edition New York Inc., 175 Fifth Avenue, New York, N.Y. 10010 U.S.A., and *Organic Synthesis*, Wiley, New York, USA. Furthermore, peptidomimetics and/or computer-aided design of appropriate derivatives and analogs can be used, for example, according to the methods described above. Methods for the lead generation in drug discovery also include using proteins and detection methods such as mass spectrometry (Cheng et al. *J. Am. Chem. Soc.* 117 (1995), 8859-8860) and some nuclear magnetic resonance (NMR) methods (Fejzo et al., *Chem. Biol.* 6 (1999), 755-769; Lin et al., *J. Org. Chem.* 62 (1997), 8930-8931). They may also include or rely on quantitative structure-action relationship (QSAR) analyses (Kubinyi, *J. Med. Chem.* 41 (1993), 2553-2564, Kubinyi, *Pharm. Unserer Zeit* 23 (1994), 281-290) combinatorial biochemistry, classical chemistry and others; see, for example, Holzgrabe and Bechtold, *Pharm. Acta Helv.* 74 (2000), 149-155.

[0122] In one embodiment, the method of the invention further comprises mixing the substance isolated or modified with a pharmaceutically acceptable carrier. Examples of carriers and methods of formulation may be found in Remington's *Pharmaceutical Sciences*.

[0123] Substances are metabolized after their in vivo administration in order to be eliminated either by excretion or by metabolism to one or more active or inactive metabolites (Meyer, *J. Pharmacokinet. Biopharm.* 24 (1996), 449-459). Thus, rather than using the actual compound or drug identified and obtained in accordance with the methods of the present invention, a corresponding formulation as a pro-drug can be used which is converted into its active form in the patient by his/her metabolism. Precautionary measures that may be taken for the application of pro-drugs and drugs are described in the literature; see, for review, Ozama, *J. Toxicol. Sci.* 21 (1996), 323-329.

[0124] The present invention also relates to a kit containing specific reagents such as those described hereinbefore useful for conducting any one of the above described methods of the present invention, containing, for example, the reporter gene construct described hereinbefore, multi-or pluripotent cells, standard compounds, and optionally culture medium, recombinant nucleic acid molecules, detection means for the reporter molecule, in particular for SEAP such as EDTA, L-Homoarginine, NBT/BCIP, fixative solution, incubation buffer, PBS, etc. Such a kit would typically comprise a compartmentalized carrier suitable to hold in close confinement at least one container. The carrier would further comprise reagents useful for performing said methods. The carrier may also contain a means for detection such as labeled enzyme substrates or the like.

[0125] Yet another aspect of the present invention relates to a method of conducting a drug discovery business, comprising:

- providing one or more assay systems as described herein for identifying a modulator of cell differentiation; and/or
- conducting therapeutic profiling of modulators identified in the previous step, or further analogs thereof, for efficacy and toxicity in animals according to the invention; and
- formulating a pharmaceutical preparation including one or more modulators identified in the previous step as having an acceptable therapeutic profile.

[0126] Utilizing the methods described above, the identity of a modulator of differentiation or a derivative thereof are determined. Agents are identified by their ability to alter the level of secreted reporter molecule. For suitable lead compounds that are identified, further therapeutic profiling of the agent, or analogs thereof, can be carried out for assessing efficacy and toxicity in animals. Those compounds having therapeutic profiles after animal testing can be formulated into pharmaceutical preparations for use in humans or for veterinary uses. The subject business method can include an additional step of establishing a distribution system for distributing the pharmaceutical preparation for sale, and may optionally include establishing a sales group for marketing the pharmaceutical preparation.

[0127] Instead of developing the identified cell differentiation modulating agents in house, further drug development can also be achieved by a different company. Thus, a further aspect of the present invention relates to a method of conducting a target discovery business comprising:

- providing one or more assay systems described herein for identifying modulators of cell differentiation;
- (optionally) conducting therapeutic profiling of modulators identified in the previous step for efficacy and toxicity in animals according to the invention; and

- licensing, to a third party, the rights for further drug development and/or sales for modulators identified in the first step, or analogs thereof.

5 [0128] For suitable lead compounds that have been identified, further profiling of the agent, or further analogs thereof, can be carried out for assessing efficacy and toxicity in animals, depending on the modalities of the agreement with the respective third party. Further development of those compounds for use in humans or for veterinary uses will then be conducted by the third party. The subject business method will usually involve either the sale or licensing of the rights to develop said compound but may also be conducted as a service, offered to drug developing companies for a fee.

10 [0129] The present invention also relates to modulators of cell differentiation identified according to the methods described above as well as to pharmaceutical compositions for use in the modulation of cell differentiation comprising such a modulator.

15 [0130] The modulator according to the invention can be combined with suitable diluents or carriers, preferably those which are pharmaceutically acceptable. Examples of such carriers, diluents and methods of formulation may be found in Remington's Pharmaceutical Sciences. To form a pharmaceutically acceptable composition suitable for effective administration, such compositions will contain an effective amount of the modulator. Carriers or diluents are usually sterile and non-toxic, and defined as vehicles commonly used to formulate pharmaceutical compositions for animal or human administration. The diluent is selected so as not to affect the biological activity of the combination. Examples of such diluents are distilled water, physiological saline, Ringer's solutions, dextrose solution, and Hank's solution. In addition, the pharmaceutical composition or formulation may also include other carriers, adjuvants, or non-toxic, non-therapeutic, non-immunogenic stabilizers and the like. A therapeutically effective dose refers to that amount of modulator which is sufficient to achieve the desired effect on differentiation of target cells.

20 [0131] Further examples of suitable pharmaceutical carriers are well known in the art and include phosphate-buffered saline solutions, emulsions, such as oil/water emulsions, various types of wetting agents, sterile solutions etc. Compositions comprising such carriers can be formulated by well known conventional methods. Accordingly, the present invention also provides a method of making a pharmaceutical composition for use in modulating cell differentiation comprising mixing a modulator of cell differentiation identified according to a method of the invention with a suitable diluent or carrier.

25 [0132] The use of a reporter gene construct, a cell, a cell aggregate, tissue, organ, implant or transplant, a non-human animal, a composition, an array or the apparatus defined herein in drug discovery or pharmacokinetic or pharmacological profiling is also a preferred embodiment of the present invention. Hence, the means and methods of the present invention described hereinbefore can be used in a variety of applications including, but not limited to, "loss of function" assays with ES cells containing homozygous mutations of specific genes, "gain of function" assays with ES cells overexpressing exogenous genes, developmental analysis of teratogenic/embryotoxic compounds in vitro, pharmacological assays and the establishment of model systems for pathological cell functions, and application of differentiation and growth factors for induction of selectively differentiated cells which can be used as a source for tissue grafts; see for review, e.g., Guan et al., *Altex* 16 (1999), 135-141.

30 [0133] As described in the examples, for the expression of the secreted human placental alkaline phosphatase protein (SEAP), a particular promoter has been used, i.e. the promoter region of the mouse alpha myosin heavy chain gene; see NCBI GenBank Accession No. U71441 (SEQ ID NO: 1). In accordance with the present invention, it could be shown that this promoter region is particularly suited for cell type-specific expression of a reporter gene, especially for the purposes of the present invention. In addition, further experiments performed in accordance with the present invention surprisingly revealed that the mouse ventricular myosin regulatory light chain gene promoter (see NCBI GenBank Accession No. AF302688; SEQ ID NO: 2) is particularly suited for the expression of the reporter gene as well. Thus, the present invention also relates to a recombinant DNA molecule as described hereinbefore in a cell type-specific reporter system, comprising the promoter of the mouse alpha myosin heavy chain gene and/or of the mouse ventricular myosin regulatory light chain gene, in particular the sequence depicted in NCBI GenBank Accession No. U71441 (SEQ ID NO: 1) and AF302688 (SEQ ID NO: 2), respectively, or a fragment thereof. Typically, the recombinant DNA molecule is a vector and comprises other functional DNA sequences such as ori, bacterial selectable marker, polyadenylation signal, multiple cloning sites, and the like. Hence, such vector may also be used to express specifically for example growth factors and the like or target cDNAs in order to elucidate their function during cell development. Thus, the present invention involves the use of the mentioned promoter regions for the expression of a DNA sequence encoding a reporter protein or a selectable marker; see supra. In a particular, the present invention relates to the expression vector described in Example 1 comprising the nucleotide sequence depicted in SEQ ID NO: 3 as well as to a corresponding vector, wherein the mouse alpha myosin heavy chain gene promoter has been replaced by the mouse ventricular myosin regulatory light chain gene promoter, and their use in the afore-described embodiments.

55 [0134] These and other embodiments are disclosed and encompassed by the description and examples of the present invention. Further literature concerning any one of the materials, methods, uses and compounds to be employed in accordance with the present invention may be retrieved from public libraries and databases, using for example electronic

devices. For example, the public database "medline" may be utilized, which is hosted by the National Center for Biotechnology Information and/or the National Library of Medicine at the National Institutes of Health. Further databases and web addresses, such as those of the European Bioinformatics Institute (EBI), which is part of the European Molecular Biology Laboratory (EMBL) are known to the person skilled in the art and can also be obtained using internet search engines. An overview of patent information in biotechnology and a survey of relevant sources of patent information useful for retrospective searching and for current awareness is given in Berks, TIBTECH 12 (1994), 352-364.

[0135] The above disclosure generally describes the present invention. A more complete understanding can be obtained by reference to the following specific examples and figure which are provided herein for purposes of illustration only and are not intended to limit the scope of the invention. The contents of all cited references (including literature references, issued patents, published patent applications as cited throughout this application and manufacturer's specifications, instructions, etc.) are hereby expressly incorporated by reference; however, there is no admission that any document cited is indeed prior art as to the present invention.

[0136] The practice of the present invention will employ, unless otherwise indicated, conventional techniques of cell biology, cell culture, molecular biology, transgenic biology, microbiology, recombinant DNA, and immunology, which are within the skill of the art.

[0137] For further elaboration of general techniques concerning stem cell technology, the practitioner can refer to standard textbooks and reviews, for example Teratocarcinomas and embryonic stem cells: A practical approach (E. J. Robertson, ed., IRL Press Ltd. 1987); Guide to Techniques in Mouse Development (P. M. Wasserman et al., eds., Academic Press 1993); Embryonic Stem Cell Differentiation in Vitro (Wiles, Meth. Enzymol. 225 (1993), 900.); Properties and uses of Embryonic Stem Cells: Prospects for Application to Human Biology and Gene Therapy (Rathjen et al., Reprod. Fertil. Dev. 10 (1998), 31.). Differentiation of stem cells is reviewed in Robertson, Meth. Cell Biol. 75 (1997), 173; and Pedersen, Reprod. Fertil. Dev. 10 (1998), 31. Besides the sources for stem cells described already above further references are provided; see Evans and Kaufman, Nature 292 (1981), 154-156; Handyside et al., Roux's Arch. Dev. Biol., 196 (1987), 185-190; Flechon et al., J. Reprod. Fertil. Abstract Series 6 (1990), 25; Doetschman et al., Dev. Biol. 127 (1988), 224-227; Evans et al., Theriogenology 33 (1990), 125-128; Notarianni et al., J. Reprod. Fertil. Suppl., 43 (1991), 255-260; Giles et al., Biol. Reprod. 44 (Suppl. 1) (1991), 57; Strelchenko et al., Theriogenology 35 (1991), 274; Sukoyan et al., Mol. Reprod. Dev. 93 (1992), 418-431; Iannaccone et al., Dev. Biol. 163 (1994), 288-292.

[0138] Methods in molecular genetics and genetic engineering are described generally in the current editions of Molecular Cloning: A Laboratory Manual, (Sambrook et al., (1989) Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press); DNA Cloning, Volumes I and II (D. N. Glover ed., 1985); Oligonucleotide Synthesis (M. J. Gait ed., 1984); Nucleic Acid Hybridization (B. D. Hames & S. J. Higgins eds. 1984); Transcription And Translation (B. D. Hames & S. J. Higgins eds. 1984); Culture Of Animal Cells (R. I. Freshney, Alan R. Liss, Inc., 1987); Gene Transfer Vectors for Mammalian Cells (Miller & Calos, eds.); Current Protocols in Molecular Biology and Short Protocols in Molecular Biology, 3rd Edition (F. M. Ausubel et al., eds.); and Recombinant DNA Methodology (R. Wu ed., Academic Press). Gene Transfer Vectors For Mammalian Cells (J. H. Miller and M. P. Calos eds., 1987, Cold Spring Harbor Laboratory); Methods In Enzymology, Vols. 154 and 155 (Wu et al. eds.); Immobilized Cells And Enzymes (IRL Press, 1986); B. Perbal, A Practical Guide To Molecular Cloning (1984); the treatise, Methods In Enzymology (Academic Press, Inc., N.Y.); Immunochemical Methods In Cell And Molecular Biology (Mayer and Walker, eds., Academic Press, London, 1987); Handbook Of Experimental Immunology, Volumes I-IV (D. M. Weir and C. C. Blackwell, eds., 1986). Reagents, cloning vectors, and kits for genetic manipulation referred to in this disclosure are available from commercial vendors such as BioRad, Stratagene, Invitrogen, and Clontech. General techniques in cell culture and media collection are outlined in Large Scale Mammalian Cell Culture (Hu et al., Curr. Opin. Biotechnol. 8 (1997), 148); Serum-free Media (Kitano, Biotechnology 17 (1991), 73); Large Scale Mammalian Cell Culture (Curr. Opin. Biotechnol. 2 (1991), 375); and Suspension Culture of Mammalian Cells (Birch et al., Bioprocess Technol. 19 (1990), 251). Other observations about the media and their impact on the culture environment have been made by Marshall McLuhan and Fred Allen.

EXAMPLES

Example 1: Generation of a vector for cardiac-specific SEAP expression

[0139] Using standard cloning procedures, a SEAP expression vector was obtained in the following way. A 5.4 kb fragment containing the promoter region of the α -mouse myosin heavy chain gene (Genbank No. U71441) was inserted into the polylinker of the pEGFP-1 vector (Clontech). The α -myosin heavy chain gene is specifically expressed by cardiac myocytes in differentiating ES cells (Gulick et al., J. Biol. Chem. 266 (1991), 9180-91855; Palermo et al., Cell Mol. Biol. Res. 41 (1995), 501-519; Morkin, Microsc. Res. Tech. 50 (2000), 522-531; Boheler et al., Circ. Res. 91 (2002), 189-201). Subsequently, the EGFP encoding sequence was removed and replaced by a SEAP encoding sequence (Berger et al., Gene 66 (1988), 1-10).

[0140] The resulting vector, designated α -MHC-SEAP, thus contains the SEAP gene under the transcriptional control

of a heart-specific promoter. Further features of the vector include the presence of a Kozak consensus sequence to allow efficient translation of the SEAP mRNA, the presence of SV40 polyadenylation signals directing proper processing of the SEAP mRNA, the presence of a neomycin resistance cassette consisting of the SV40 early promoter, the neomycin/kanamycin resistance gene of Tn5 and polyadenylation signals from the Herpes simplex virus thymidine kinase gene to allow selection of stably transfected ES cells, and the presence of a bacterial promoter upstream of this cassette to confer kanamycin resistance in *E. coli*.

Example 2: Generation of ES cell transfectants

[0141] The α -MHC-SEAP vector was linearized by restriction endonuclease digestion and introduced into D3 mouse embryonic stem (ES) cells (American Type Culture Collection) by electroporation. Following neomycin selection, single ES cell colonies were isolated and expanded. ES cell culture and transfection as well as selection of stable transfectants was done using standard procedures (Torres and Kühn, Laboratory protocols for conditional gene targeting. Oxford University Press, (1997) New York).

Example 3: Differentiation of ES cells into cardiac cells in the presence of retinoic acid

[0142] The presence of excessive retinoic acid has striking effects on early heart development *in vivo* (Osmond et al., Development 113 (1991), 1405-1417; Yutzey et al., Development 120 (1994), 871-883; Dickman and Smith, Dev. Dyn. 206 (1996), 39-48; Drysdale et al., Dev. Biol. 188 (1997), 205-215). Furthermore, all-*trans* retinoic acid (CAS No. 302-79-4) was shown to inhibit the generation of cardiomyocytes from ES cells *in vitro* (Seiler et al. ALTEX 19 Suppl. 1 (2002), 55-63). Therefore, ES cells stably transfected with the α -MHC-SEAP vector were treated with retinoic acid at different concentrations and subjected to a differentiation protocol that resulted in the generation of cardiac cells. If secreted reporter, here SEAP, activity can indeed be used to quantify ES cell-derived cardiomyocytes, the amount of SEAP activity in culture supernatants should correlate inversely with the concentrations of retinoic acid present in the cultures.

[0143] All incubations of cell cultures were performed at 37 °C in a humidified atmosphere containing 5 % CO₂.

ES cell aggregation

[0144] ES cells stably transfected with the α -MHC-SEAP vector (see Example 2) were trypsinized to obtain a single cell suspension. Cells were collected by centrifugation (800 g for 5 min) and resuspended in Iscove's Modified Dulbecco's Medium (IMDM, Invitrogen) supplemented with 20 % (v/v) fetal bovine serum (FBS, Invitrogen) at a density of 2x10⁶ cells/ml. To aggregate ES cells, 4 ml of this suspension were incubated on a 6 cm bacteriological dish (Greiner) on a rocking platform (GFL 3006) with agitation (50 rpm). After 6 hours, 2 ml of that culture were added to 13 ml IMDM containing 20 % FBS in a T25 flask (Falcon). The flask was incubated with rocking (50 rpm; GFL 3006) for 18 hours. During this procedure ES cell aggregates (embryoid bodies; EBs) were formed.

ES cell differentiation in the presence of retinoic acid

[0145] All-*trans* retinoic acid (Sigma) was dissolved in dimethyl sulfoxide (DMSO, Sigma) to obtain 10⁻⁴ M, 10⁻⁵ M, 10⁻⁶ M, 10⁻⁷ M, 10⁻⁸ M, and 10⁻⁹ M stock solutions. In 10 cm petri dishes (bacteriological grade, Greiner) medium was prepared consisting of IMDM supplemented with 20 % FBS and retinoic acid added from above stocks to yield final concentrations of 10⁻⁷ M, 10⁻⁸ M, 10⁻⁹ M, 10⁻¹⁰ M, 10⁻¹¹ M, and 10⁻¹² M retinoic acid, respectively. One dish received DMSO (final concentration 0.1 % (v/v)) without retinoic acid (solvent control). Each dish contained 10 ml of medium. 70 EBs were transferred into each petri dish and incubated for 4 days.

[0146] Subsequently, EBs were transferred to 6-well plates (tissue culture grade; Becton-Dickinson). Each well contained 3 ml IMDM with 20 % FBS and retinoic acid and DMSO as described above for the culture in 10 cm dishes. 2 wells were set up for each concentration of retinoic acid and 2 wells as solvent controls. To each well 20 EBs were transferred from the respective 10 cm dish. Plates were incubated for 7 days. Subsequently, culture medium was exchanged with 2 ml knockout™ D-MEM (Invitrogen) supplemented with 20 % (v/v) knockout™ SR (Invitrogen). Samples of cell culture supernatants were collected after incubation of EBs for further two days.

Determination of SEAP activity

[0147] Samples were assayed for SEAP activity using the Great EscAPe SEAP Fluorescence Detection Kit (Becton-Dickinson) following the manufacturer's instructions. Fluorescence was measured using a microplate reader (Safire, Tecan). Background activity was determined by assaying a sample of fresh medium (knockout™ D-MEM supplemented with 20 % (v/v) knockout™ SR).

EP 1 644 485 B9

[0148] Results are shown in Fig. 1. Concentrations of retinoic acid below 10^{-9} M had no influence on SEAP activity as compared to controls. SEAP activity decreased sharply at 10^{-8} M retinoic acid. At higher concentrations no activity was observed.

[0149] Thus, a concentration-dependent effect of retinoic acid on SEAP activity in culture supernatants is clearly observed. Moreover, these data are consistent with the concentration-dependent inhibition of cardiomyocyte generation by retinoic acid described previously (Seiler et al., 2002, supra). Therefore, the results indicate the suitability of the reporter system presented here to quantify ES cell-derived cardiomyocytes and its usefulness for the monitoring of the differentiation process of ES cells.

10 SEQUENCE LISTING

[0150]

15 <110> Axiogenesis AG
<120> Secreted Proteins As Markers For Cell Differentiation
<130> AX02A03/P-WO
20 <160> 4
<170> PatentIn version 3.1
<210> 1
25 <211> 5443
<212> DNA
<213> Mus musculus
<220>
30 <221> promoter
<222> (1)..(5443)
<223> alpha myosin heavy chain gene, promoter region
<220>
35 <221> promoter
<222> (2)..(5442)
<223> promoter region contained in SEQ ID NO 3
<220>
40 <221> 5'UTR
<222> (4369)..(4389)
<223> exon1
<220>
45 <221> 5'UTR
<222> (5071)..(5139)
<223> exon 2
<220>
50 <221> 5'UTR
<222> (5431)..(5443)
<223> exon 3
<400> 1
55

EP 1 644 485 B9

ggatcctgca aggtcacaca agggctctcca cccaccaggt gccctagtct caatttcagt 60
 ttccatgcct tgttctcaca atgctggcct cccagagct aatttggact ttgtttttat 120
 5 ttcaaaaggg cctgaatgag gagtagatct tgtgctaccc agctctaagg gtgcccgatga 180
 agccctcaga cctggagcct ttgcaacagc cctttaggtg gaagcagaat aaagcaattt 240
 10 tccttaaagc caaaatcctg cctctagact cttcttctct gacctcggtc cctgggctct 300
 aggggtgggga ggtggggcct ggaagaagaa ggtggggaag tggcaaaagc cgatccctag 360
 ggccctgtga agttcggagc cttccctgta cagcactggc tcatagatcc tcctccagcc 420
 15 aaacatagca agaagtgata cctcctttgt gacttcccca ggcccagtac ctgtcagggtt 480
 gaaacaggat ttagagaagc ctctgaactc acctgaactc tgaagctcat ccaccaagca 540
 agcacctagg tgccactgct agttagtatc ctacgctgat aatatgcaga gctggggccac 600
 20 agaagtctctg ggggtgtagga actgaccagt gacttttcag tcggcaaagg tatgaccccc 660
 tcagcagatg tagtaatgtc cccttagatc ccatcccagg caggtctcta agaggacatg 720
 25 ggatgagaga tgtagtcatg tggcattcca aacacagcta tccacagtgt cccttgcccc 780
 ttccacttag ccaggaggac agtaacctta gcctatcttt cttcctcccc atoctcccag 840
 gacacacccc ctggtctgca gtattcattt cttccttcac gteccctctg tgacttccat 900
 30 ttgcaaggct tttgacctct gcagctgctg gaagatagag tttggcccta ggtgtggcaa 960
 gccatctcaa gagaaagcag acaacagggg gaccagattt tggaaggatc aggaactaaa 1020
 35 tcactggcgg gcctgggggt agaaaaaaga gtgagtgagt ccgctccagc taagccaagc 1080
 tagtccccga gatactctgc cacagctggg ctgctcgggg tagctttagg aatgtggggtc 1140
 tgaaagacaa tgggattgga agacatctct ttgagtctcc cctcaacccc acctacagac 1200

40

45

50

55

EP 1 644 485 B9

5 acactcgtgt gtggccagac tctgttcaa cagccctctg tgttctgacc actgagctag 1260
 gcaaccagag catgggccct gtgctgagga tgaagagttg gttaccaata gcaaaaacag 1320
 caggggaggg agaacagaga acgaaataag gaaggaagaa ggaaaggcca gtcaatcaga 1380
 10 tgcagt caga agagatggga agccaacaca cagcttgagc agaggaaaca gaaaagggag 1440
 agattctggg cataaggagg ccacagaaag aagagcccag gccccccaag tctctcttt 1500
 ataccctcat cccgtctccc aattaagccc actcttcttc ctagatcaga cctgagctgc 1560
 agcgaagaga cccgtagggg ggatcacact ggatgaagga gatgtgtgga gaagtccagg 1620
 15 gcaacctaa agccagagcc taaaagagca agagataaag gtgcttcaaa ggtggccagg 1680
 ctgtgcacac agagggtcga ggactgggtg tagagcctca agataaggat gatgctcaga 1740
 atgggcgggg ggggggattc tggggggggg agagagaagg tgagaaggag cctggaacag 1800
 20 agaatctgga agcgttgga acgataccat aaaggaaga acccaggcta cctttagatg 1860
 taaatcatga aagacagggg gaagggagc tggagagagt agaaggacc cggggcaaga 1920
 catggaagca aggacaagcc aggttgagcg ctccgtgaaa tcagcctgct gaaggcagag 1980
 25 ccctggtatg agcaccagaa cagcagaggc tagggttaat gtcgagacag ggaacagaag 2040
 gtagacacag gaacagacag agacggggga gccaggtaac aaaggaatgg tcttctcac 2100
 ctgtggccag agcgtccatc tgtgtccaca tactctagaa tttcatcag actgcagggc 2160
 30 tggcttggga ggcagctgga aagagtatgt gagagccagg ggagacaagg gggcctagga 2220
 aaggaagaag agggcaaacc aggccacaca agagggcaga gccagaact gagttaactc 2280
 ctctctgtt gcatcttcca taggaggcag tgggaactct gtgaccacca tccccatga 2340
 35 gccccacta cccataccaa gtttggcctg agtggcattc taggttccct gaggacagag 2400
 cctggccttt gtctcttggg cctgacccaa gctgacccaa tttctcagt accttatcat 2460
 gccctcaaga gcttgagaac caggcagtga catattagc catgggctaa ccctggagct 2520
 40 tgcacacagg agcctcaagt gacctccagg gacacagctg cagacaggtg gcctttatcc 2580
 ccaaagagca accatttggc ataggtggct gcaaatggga atgcaagggt gaatcaggtc 2640
 cctcaagaa tactgcatgc aagacctaa acccctggag agaggggtat gctcctgccc 2700
 45 ccaccacca taaggggagt gaactatcct agggggctgg cgacctggg gagacaccac 2760
 attactgaga gtgctgagcc cagaaaaact gaccgcccctg tctcctgccc acctccacac 2820
 tctagagcta tattgagagg tgacagtaga taggggtggg gctggtagca gggagagtgt 2880
 50 tctgggtgt gaggggtag gggaaagcca gagcagggga gtctggcttt gtctcctgaa 2940
 cacaatgtct acttagttat aacaggcatg acctgctaaa gaccaacat ctacgacctc 3000
 55 tgaaaagaca gcagccctgg aggacagggg ttgtctctga gccttgggtg cttgatgggtg 3060
 ccacaaagga gggcatgagt gtgagtataa ggccccagga gcgttagaga agggcacttg 3120

EP 1 644 485 B9

ggaaggggtc agtctgcaga gccctatcc atggaatctg gagcctgggg ccaactggtg 3180
 taaatctctg gccctgccag gcattcaaag cagcacctgc atcctctggc agcctgggga 3240
 5 ggcggaaggg agcaaccccc cacttatacc ctttctccct cagccccagg attaacacct 3300
 ctggccttcc cccttcccac ctcccatcag gagtggaggg ttgcagaggg agggtaaaaa 3360
 cctacatgtc caaacatcat ggtgcacgat atatggatca gtatgtgtag aggcaagaaa 3420
 10 ggaaatctgc aggcttaact gggttaatgt gtaaagtctg tgtgcatgtg tgtgtgtctg 3480
 actgaaaacg gccatggctg tgcagctgtt cagttctgtg cgtgagggta ccgactgca 3540
 ggtttgtgtg taaattgcc aaggcaaagt gggtgaatcc cttccatggt ttaaagagat 3600
 15 tggatgatgg cctgcatctc aaggaccatg gaaaatagaa tggacactct atatgtgtct 3660
 ctaagctaag gtagcaaggt ctttgaggga cacctgtcta gagatgtggg caacagagac 3720
 20 tacagacagt atctgtacag agtaaggaga gagaggaggg ggtgtagaat tctcttacta 3780
 tcaaagggaa actgagctgt gcacctgcaa agtggatgct ctccctagac atcatgactt 3840
 tgtctctggg gagccagcac tgtggaactt caggtctgag agagtaggag gctccoctca 3900
 25 gcctgaagct atgcagatag ccagggttga aagggggaag ggagagcctg ggatgggagc 3960
 ttgtgtgttg gaggcagggg acagatatta agcctggaag agaaggtgac ccttaccag 4020
 ttgttcaact cacccttcag attaaaaata actgaggtaa ggcctgggt aggggaggtg 4080
 30 gtgtgagacg ctctgtctc tcctctatct gcccatcggc cctttgggga ggaggaatgt 4140
 gcccaaggac taaaaaagg ccatggagcc agaggggcca gggcaacaga cctttcatgg 4200
 gcaaacctg gggccctgct gtctctctgt cacctccaga gccaaaggat caaaggagga 4260
 35 ggagccagga caggagggaa gtgggagggg ggtcccagc agaggactcc aaatntaggc 4320
 agcaggcata tgggatggga tataaagggg ctggagcact gagagctgtc agagatttct 4380
 ccaaccag taagagggag tttcgggtgg gggctcttca cccacaccag acctctcccc 4440
 40 acctagaagg aaactgcctt tcctggaagt ggggttcagg ccggtcagag atctgacagg 4500
 gtggccttcc accagcctgg gaagtctca gtggcaggag gttccacaa gaaacactgg 4560
 45 atgccccctc ccttacgctg tcttctccat ctctctctg gggatgctcc tccccgtctt 4620
 ggtttatctt ggctcttcgt cttcagcaag atttgccctg tgctgtccac tccatcttcc 4680
 tctactgtct ccgtgccttg ccttgcttcc ttgctgttcc tctcttcca cccatttctc 4740
 50 acttcacctt ttctccccct ctcatctgta ttcctcttcc ctctcttctc tcttctcttc 4800
 ctctcttctc tcttctcttc ctttctccct tcttctcttc ctctcttctc tcttctcttc 4860
 ctctcttctc gtgtcagagt gctgagaatc acacctgggg tcccaccct tatgtaaaca 4920
 55 atcttccagt gagccacagc ttcagtgtct ctgggtgctc tcttacctc ctcacccct 4980

EP 1 644 485 B9

ggcttgtcct gttccatcct ggtcaggatc tctagattgg tctcccagcc tctgctactc 5040
 5 ctcttctctgc ctgttctctct ctctgtccag ctgcgccact gtggtgcctc gttccagctg 5100
 tgggtccacat tcttcaggat tctctgaaaa gttaaccagg tgagaatggt tcccctgtag 5160
 acagcagatc acgattctcc cggaagtcag gcttccagcc ctctctttct ctgcccagct 5220
 10 gcccggcact cttagcaaac ctcaggcacc cttacccac atagacctct gacagagaag 5280
 caggcacttt acatggagtc ctggtgggag agccataggc tacggtgtaa aagaggcagg 5340
 gaagtgggtgg tgtaggaaag tcaggacttc acatagaagc ctagcccaca ccagaaatga 5400
 15 cagacagatc cctcctatct cccccataag agtttgagtc gac 5443

20 <210> 2
 <211> 6298
 <212> DNA
 <213> Mus musculus
 25 <220>
 <221> promoter
 <222> (1)..(5445)
 <223> ventricular myosin regulatory light chain gene (AF302688)

30 <220>
 <221> 5'UTR
 <222> (5446)..(5486)
 <223> exon 1

35 <220>
 <221> exon
 <222> (5487)..(5489)
 <223> exon 1

40 <220>
 <221> exon
 <222> (6209)..(6298)
 <223> exon 2

45 <400> 2

50

55

EP 1 644 485 B9

ctcgagtgct gggattaaag gcatgcacca ccatgctcag cctgttttct tttttaagag 60
 ttaatctttt taattatgtg tatgtatgtc tttgcatgga tatgcccacg agagtgcatg 120
 5 tgccctggaa gaccagaagg gggtgacaaa cccctgcagt tttgagcctc ctggcctggg 180
 tgctgggaat caaacttaat ttctctagaa gagcagagtc ctcttaacac ccaagcctc 240
 10 ttgccagccc ttattttgtt tgggtgggtg gtttttgcca aagctaggag ttccagcccc 300
 agtcttttat actctgccct catggcttct gacatctcca actctgccag gggctgactc 360
 ttatcttcag aaagcaattg ttaoctttgac cccagcagt gctgagccac caccagggc 420
 15 ctgaggctag aagaaaatgt accctccttc catggctcctc ttcagaaagc actgtgaacc 480
 caggtaaagg tagcaggtcc aggttcagat gtagtgtcca cagcctgtgc aaaaaggacc 540
 cttcacttcc aagcttgccc cacctgatca gaccactctc cagatctggg gaaaacggta 600
 20 gcaggctctt cacccaaca ggagtcccca gggcacacaa gatattgcct ttgattttgt 660
 ccttatgaca accctgcaaa taaaatogtc atcatgcca ctctacagat tagaatactg 720
 25 aagctgagag caaaaaccta cctgatgtca cactgctgct caatgactaa gcaacgaaaa 780
 tcaaaagtga atattccgc aggctocagt cttgcagatg acaaatgctc tgtcaccgtc 840
 acatttgggt ccatgttctg aaatcctctg tttcacctc ctagaacc cagatagtac 900
 30 ctaaatagct gagtccattc acctggcctt ggctttctgc taaggaatat gtcagacatc 960
 ttcaggattc ttcaaactg ttctgagtag aaatctcttc aggcctggga gctgtttcct 1020
 35 ctgagcagaa agccccatg tggcacaggc caactcccc acaaccagaa ccatcatcag 1080
 tcacaactgc acttctctc atgccgaaga aactttttt ttcagtcttg gatggatgct 1140
 ggaaccatcg gatcctgtaa cccgcttctc cacctcagc acagacgtca ggacttgagg 1200
 40 ctccctcctg ctgctctctt ctgcaactgca cttgaatttc cctgaggttt ggcatttggg 1260
 gtttttgttt ggcttgttc tttgcttgcc tagaggaata atcaatgctt aggcctttta 1320
 tagcaaaggc atttagtggg tcaaccaagc actcaggaga tagacaggag ggtcagaatt 1380
 45 caaggctatc ctttgctaca caatgagttc agggctcagcc tgggctacac gagatccaat 1440
 ctaaaataaa caaaaaataa aataattgat atttcttctc tgtatattat agttatactg 1500
 50 tagactgttg gggatacatt ctccaagagt ctcaaagttc atctccactg agttaattaa 1560
 tgttgttact ataacacaac actagagtct ggttcgttta caaatacaaa agatttattt 1620
 tgggctggag agatggctca gagctgactg ctcttccaaa ggtcctgagt tccaatccca 1680
 55 gcaaccacat ggtggctcga aaccatctgt aatgggatct gatgccttct tctagtgtgt 1740

EP 1 644 485 B9

ctgaagacag ctatggtgta ctcacataca taaaataaat aaataaatct taagagagag 1800
 atttgtttct acaaaggcta gatgctactg agagtaaagg gtttagaact ccgttttcct 1860
 5 cttcttacta actcactaat cccatcttgg gggggggagg ggaagcttc atgacttcac 1920
 ctaacctcgt tcacctctcc tagaccttac ctctatcgc taccaatctc tgatttgagg 1980
 atcaaatttt caaccagga gcttaggga gacaaatgta aaccocagta tcccctgact 2040
 10 cccggtgtac actggatcct gcacacagta gggctccaat aaatactgaa agtccttaga 2100
 atgggggcaa aatcattttt gtgtttataa atatgacca catgttctct catcttttaa 2160
 aattgtcaga gtaatttctc tctctctctc tctctctctc tctgtgtgtg tgtgtgtgtc 2220
 15 tgtgtctgtg tgtgtgtctg tgtctgtgtc tgtgtgtctg tgtgtgtgta ctcacatcca 2280
 agtgggtttg ggtacctgtc atgtggacat gtatatgttg gtagaagcca gaagtcaacc 2340
 ttgtgtgtca tttctcagag gtgatccatc ttattttttg agacagggtc tctcactgag 2400
 20 gccggggact tactgttttt aggttacacc tgctggccag caagccagag agaccgagag 2460
 agacgggtctg tctccatctc tccagcgaca ggctttcaga cccacaccac catgcccagc 2520
 tttgatgtgg gtctgggttt tgaggagtag aattcaggac ctcttgctga gccatctccc 2580
 25 cagccactga acataattca tatataatct ggcttttggt ccttttggtg gtgcagggtg 2640
 tgttttggtt tgttctttgc tgtgtattat tctgtgcatt taagcttttt ttttttggtg 2700
 ctacctggga gggacactga acagccagaa aggccaggcc gaggcttcac tgatggggat 2760
 30 gtgagcccgg gaatgctggc agctgccggg agctggaaag ggcaaaggaa aggactgtct 2820
 ccgcatccac ggtggaogca gccctctgcc cgatttctat ttctggccac cagctctgcc 2880
 aggtagcgag ctggctgct ctgagctgcc tgggtttgcc gttgtatttt cctactagca 2940
 tgggaaagcg tgatcagctt gctttgttct caattgttcc agaagctctg ccggtcccct 3000
 ccaggactcc tgagtctctg ctccgtggta ctggggctg gctctcaaag ttctaggctg 3060
 40 cagaaatctc acaagcgcac gagcttagag tcccagggtg gatgtccacc aagagcccag 3120
 ggacaaagca ttgacagctc ctgtgtgctc cacgtctccc cccaccccca cccctacccc 3180
 caggaactgt gagaggagtg cagagcccct cccccaggcc tttccaacaa ggactcctgg 3240
 45 aggacccttg ggtttttaac accaaatcac caaatgttcc ccacgcagca acacaaacca 3300
 gctcttctc atacagcacg gtgggccagt ggaccatggg gacaggttac ctctgtgggc 3360
 ccaggctcac ggtaaactct aacctcaatc tgtagcctcc cacagccatt tgcgggtcac 3420
 50 cttgcttctc agccaccgtg tggcacttgg caagtacgt gtgcctcaac acaataagaa 3480
 gccaaaggaa taggggcttt gcttaactgg tacagcagt tagcccaagc tagccttgaa 3540
 ctcactatgt agccaaggac gatcataaac tcttgatcct cccgcttcag agtctgggt 3600
 55 gttgagataa caggtgtggg tcaactccca cccttctct aatagcaatc aatgtgtggc 3660

EP 1 644 485 B9

cacatgtttg tgcctcacag attaaaacca tcttgacctg aggacgaaat gactaacagt 3720
 tgcctcctga aggttgcctg gatctcatct ttataatccc agcaatcaag gggagtgggg 3780
 5 gatcaggagt tcaaagtcag cccagcctgg gctacatgag accctgtctt gaaaaatgga 3840
 ggaattaagc tgggcgtggg gccgcactcc tttaatccca gcacttggga ggtagaggca 3900
 10 ggcggacttc tgagttcgag gccagcctgg tctacaaagt gagttccagg acagccacag 3960
 ctatacagag aaaccctgtc tcgaaaaacc agaaagaaag aaagagagaa agaaagaaag 4020
 aaagaaagaa agaaagaaag aaagaaagga aggaaggaag gaaggaagga aaggaaggaa 4080
 15 ggaaggaagg aaagaaagaa agaaagaaag aaagaaagac agacagaaag aaaggttagg 4140
 aaagaaagaa aggaaagaa agaaagaaag aaagaaagaa agaaagaaag aaagaaagaa 4200
 agacagaaag aaaggtttgg aaagaaagaa aggaaaagaa agaaagaaag agagaaagag 4260
 20 agaaagaaag aaagaaaaga aaagagagaa aagaaaagaa aagaaaagaa aagaaaagaa 4320
 agaaaaaaaa gaaaagaaaa gaaagaaaag aaaaggaagg aagaaaagaa aagaaaaatg 4380
 gaggagttaa ccctatgttt cctttttttt tattcatcat tggtgaggct atcctcagct 4440
 25 acatatcaag ttcaagccag cctgggctac atgagaccct gcctcaaaaa agaaaaggag 4500
 ccagtgtagc gacatactcc cgtcctccca gcacttggga gacagaggct actccactgc 4560
 tgtctccagc agccggcctg cctccctgag cctcattttt ttcataacat ggggacccaa 4620
 30 ctgctaaggt gaccttgctc ccatggggtg actggagact tgagagtgaa gtggttatca 4680
 tttgtccagt ctgtgaacaa atggcagcct ccaaggtggt tttgtgttca aaggaggaca 4740
 tgggacaggg agaggccagg gagaagagcc caccctcagg agtaggctgt ccccgtaag 4800
 35 ctgggtgggg acaaaaagca gagaagcaga ggcagaggac aagcgtgggt gacatttgag 4860
 caaagatggg aatgtgccag aggctgcccc agatgtgcat gtgcaaaggc cctgagggtc 4920
 aagggtgcct ggatccagag ccaaaagctc aggcctccctc ctctcttcc tctcttctc 4980
 40 cctcttctc ctcttctcc tctccctctc ctccctctc ccccttctc tctctctcc 5040
 ctctctctc tctctctcc ccttcttctc cctcccttc ctctctctc tctctctct 5100
 ctctctctc ctctctctc tctctctctc gctctctctc ctctctctc tgggttactc 5160
 45 tccccatta gacaatggca ggaagagag cacacccat catcccagg ccaggcccca 5220
 gccactgact ctttaacctt gaaggcattt ttgggtctca cgtgtccacc caggcgggtg 5280
 50 gccgcctttg agcagctctt acttcagaag aacggcatgg agtggggggg ggggggctta 5340
 ggtggcctcc gcctcaccta caactgocaa aagtggatcat ggggttattt ttaaccccag 5400
 gggagaggta tttattgttc cacagcaggg gcagaggcca gcaggctcct cgaactctcc 5460
 55 agaggtggca actggcctca gacacc atg gtgagtggtc agtaaaccct tgagaagaga 5519
 Met

EP 1 644 485 B9

5
<220>
<221> polyA_signal
<222> (9401)..(9406)
<223> Herpes simplex virus thymidine kinase polyadenylation signal

10
<220>
<221> polyA_signal
<222> (9414)..(9419)
<223> Herpes simplex virus thymidine kinase polyadenylation signal

15
<220>
<221> terminator
<222> (9163)..(9165)
<223> Kanamycin/neomycin resistance gene

20
<220>
<221> ATG
<222> (8371)..(8373)
<223> Kanamycin/neomycin resistance gene

25
<220>
<221> promoter
<222> (8242)..(8248)
<223> SV40 early promoter element

30
<220>
<221> repeat_region
<222> (8167)..(8230)
<223> SV40 early promoter

35
<220>
<221> enhancer
<222> (8018)..(8163)
<223> SV40 early promoter

40
<220>
<221> rep_origin
<222> (8187)..(8322)
<223> SV40 origin of replication

45
<220>
<221> -10_signal
<222> (7931) .. (7936)
<223> Ampicillin resistance (b-lactamase) promoter

50
<220>
<221> -35_signal
<222> (7908)..(7913)
<223> Ampicillin resistance (b-lactamase) promoter

55
<220>
<221> polyA_signal
<222> (7294) .. (7299)
<223> SV40 early mRNA polyadenylation signal

<220>
<221> polyA_signal
<222> (7323)..(7328)

EP 1 644 485 B9

<223> SV40 early mRNA polyadenylation signal

<220>

<221> mature protein

5 <222> (5609) .. (7114)

<223> SEAP

<220>

<221> start codon

10 <222> (5558)..(5560)

<223> ATG of the Secreted alkaline phosphatase (SEAP) gene

<220>

<221> sig_peptide

15 <222> (5558)..(5608)

<223> SEAP

<400> 3

20 tagttattac tagcgctacc ggactcagat ctcgagctca agotttogaat tctgcagtcg 60
acggtaccgc gggcccgatc ctgcaaggtc acacaagggt ctccaccac caggtgcct 120
25 agtctcaatt tcagtttcca tgccttggtc tcacaatgct ggcctccca gagctaattt 180
ggactttggt tttatttcaa aagggcctga atgaggagta gatcttgtgc taccagctc 240
taagggtgcc cgtgaagccc tcagacctgg agcctttgca acagccctt aggtggaagc 300
30 agaataaagc aattttcctt aaagccaaaa tctgcctct agactcttct tctctgacct 360
cggtccttg gctctagggt ggggaggtgg ggcttgaag aagaagggtg ggaagtggca 420
35 aaagccgatc cctagggccc tgtgaagttc ggagccttcc ctgtacagca ctggctcata 480

40

45

50

55

EP 1 644 485 B9

gatcctcctc cagccaaaca tagcaagaag tgatacctcc tttgtgactt ccccaggccc 540
 agtacctgtc aggttgaaac aggatTTaga gaagcctctg aactcacctg aactctgaag 600
 5 ctcattccacc aagcaagcac ctaggTgcca ctgctagtta gtatcctacg ctgataatat 660
 gcagagctgg gccacagaag tcttggggTg taggaactga ccagtgactt ttcagtcggc 720
 aaaggTatga cccctcagc agatgtagta atgtccctt agatcccatc ccaggcaggt 780
 10 ctctaagagg acatgggatg agagatgtag tcatgtggca ttccaaacac agctatccac 840
 agtgtccctt gcccttcca cttagccagg aggacagtaa ccttagccta tctttcttcc 900
 tccccatcct cccaggacac accccttggT ctgcagtatt catttcttcc ttcacgtccc 960
 15 ctctgtgact tccatttgca aggttttga cctctgcagc tgctggaaga tagagtttg 1020
 ccctaggTgt ggcaagccat ctcaagagaa agcagacaac agggggacca gattttggaa 1080
 ggatcaggaa ctaaactact ggcgggcctg ggggtagaaa aaagagtgag tgagtccgct 1140
 20 ccagctaagc caagctagtc cccgagatac tctgccacag ctgggctgct cggggtaget 1200
 ttagaatgt gggTctgaaa gacaatggga ttggaagaca tctctttgag tctccctca 1260
 accccaccta cagacacact cgtgtgtggc cagactcctg ttcaacagcc ctctgtgttc 1320
 25 tgaccactga gctaggcaac cagagcatgg gccctgtgct gaggatgaag agttggttac 1380
 caatagcaaa aacagcaggg gagggagaac agagaacgaa ataaggaagg aagaaggaaa 1440
 ggccagtcaa tcagatgcag tcagaagaga tgggaagcca acacacagct tgagcagagg 1500
 30 aaacagaaaa gggagagatt ctgggcataa ggaggccaca gaaagaagag cccaggcccc 1560
 ccaagtctcc tctttatacc ctcatcccgt ctccaatta agcccactct tcttcctaga 1620
 35 tcagacctga gctgcagcga agagaccctg agggaggatc aactggatg aaggagatgt 1680
 gtggagaagt ccagggaac ctaagagcca gagcctaaaa gagcaagaga taaaggTgct 1740
 tcaaaggTgg ccaggctgtg cacacagagg gtcgaggact ggtggtagag cctcaagata 1800
 40 aggatgatgc tcagaatggg cggggggggg gattctgggg gggggagaga gaaggTgaga 1860
 aggagcctgg aacagagaat ctggaagcgc tggaaacgat accataaagg gaagaacca 1920
 ggctaccttt agatgtaaT catgaaagac agggagaagg gaagctggag agagtagaag 1980
 45 gaccccgggg caagacatgg aagcaaggac aagccaggTt gagcgtccg tgaaatcagc 2040
 ctgctgaagg cagagccctg gtatgagcac cagaacagca gaggctaggg ttaatgtcga 2100
 gacagggaac agaaggTaga cacaggaaca gacagagacg ggggagccag gtaacaaagg 2160
 50 aatggTcctt ctcacctgtg gccagagcgt ccatctgtgt ccacatactc tagaatgttc 2220
 atcagactgc agggctggct tgggaggcag ctggaaagag tatgtgagag ccaggggaga 2280
 caagggggcc taggaaagg aagaagggc aaaccaggcc acacaagagg gcagagccca 2340
 55 gaactgagTt aactccttcc ttgttgcatc ttccatagga ggcagtggga actctgtgac 2400

EP 1 644 485 B9

caccatcccc catgagcccc cactacccat accaagtttg gcctgagtgg cattctaggt 2460
 5 tccctgagga cagagcctgg cctttgtctc ttggacctga cccaagctga cccaatgttc 2520
 tcagtacctt atcatgccct caagagcttg agaaccaggc agtgacatat taggccatgg 2580
 gctaaccctg gagcttgcac acaggagcct caagtgcct ccagggacac agctgcagac 2640
 10 aggtggcctt tatccccaaa gagcaaccat ttggcatagg tggctgcaaa tgggaatgca 2700
 aggttgaatc aggtcccttc aagaatactg catgcaagac ctaagacccc tggagagagg 2760
 ggtatgctcc tgccccacc caccataagg ggagtgaact atcctagggg gctggcgacc 2820
 15 ttggggagac accacattac tgagagtgtc gagcccagaa aaactgaccg ccctgtgtcc 2880
 tgcccacctc cacactctag agctatatg agaggtgaca gtagataggg tgggagctgg 2940
 tagcaggagg agtgttctct ggtgtgaggg tgtaggggaa agccagagca ggggagtctg 3000
 20 gctttgtctc ctgaacacaa tgtctactta gttataacag gcatgacctg ctaaagaccc 3060
 aacatctacg acctctgaaa agacagcagc cctggaggac aggggttgtc tctgagcctt 3120
 ggggtgcttga tggtgccaca aaggagggca tgagtgtgag tataaggccc caggagcgtt 3180
 25 agagaagggc acttgggaag ggtcagctc gcagagcccc tatccatgga atctggagcc 3240
 tggggccaac tgggtgaaat ctctgggct gccaggcatt caaagcagca cctgcacct 3300
 ctggcagcct ggggagggcg aaggagcaaa cccccactt ataccctttc tccctcagcc 3360
 30 ccaggattaa caoctctggc ctccccctt cccacctccc atcaggagtg gagggttgca 3420
 gagggagggg aaaaacctac atgtccaaac atcatggtgc acgatatatg gatcagtatg 3480
 35 tgtagaggca agaaagggaa tctgcaggct taactgggtt aatgtgtaaa gtctgtgtgc 3540
 atgtgtgtgt gtctgactga aaacgggcat ggctgtgcag ctgttcagtt ctgtgcgtga 3600
 ggttaccaga ctgcaggttt gtgtgtaaat tgcccaaggc aaagtgggtg aatcccttc 3660
 40 atggtttaa gagattgat gatggcctgc atctcaagga ccatggaaaa tagaatggac 3720
 actctatatg tgtctctaag ctaaggtagc aaggctcttg gaggacacct gtctagagat 3780
 gtgggcaaca gagactacag acagtatctg tacagagtaa ggagagagag gaggggtgt 3840
 45 agaattctct tactatcaaa gggaaactga gtcgtgcacc tgcaaagtgg atgctctccc 3900
 tagacatcat gactttgtct ctggggagcc agcactgtgg aacttcaggt ctgagagagt 3960
 aggaggctcc cctcagcctg aagctatgca gatagccagg gttgaaagg ggaagggaga 4020
 50 gcctgggatg ggagcttggt tgttgaggc aggggacaga tattaagcct ggaagagaag 4080
 gtgacctta ccagttgtt caactcacc ttcagattaa aaataactga ggtaagggcc 4140
 tgggtagggg aggtggtgtg agacgctcct gtctctcctc tatctgcca tggcccttt 4200
 55 ggggaggagg aatgtgcca aggactaaaa aaaggccatg gagccagagg ggcgagggca 4260

EP 1 644 485 B9

acagaccttt catgggcaaa ccttggggcc ctgctgtcct cctgtcacct ccagagccaa 4320
 gggatcaaag gaggaggagc caggacagga gggaggtggg agggaggggc ccagcagagg 4380
 5 actccaaatt taggcagcag gcatatggga tgggatataa aggggctgga gcaactgagag 4440
 ctgtcagaga tttctccaac ccaggtaaga gggagtttcg ggtgggggct cttcaccac 4500
 accagacctc tccccaccta gaaggaaact gcctttcctg gaagtggggg tcaggccggg 4560
 10 cagagatctg acaggggtggc cttccaccag cctgggaagt tctcagtggc aggaggtttc 4620
 cacaagaaac actggatgcc ccttccctta cgctgtcttc tccatcttcc tcctggggat 4680
 gctcctcccc gtcttggttt atcttggttc ttcgtcttca gcaagatttg cctgtgctg 4740
 15 tccactccat ctttctctac tgtctcctg ccttgccttg ccttcttgcg tgccttctc 4800
 ttccacccat ttctcacttc accttttctc cccttctcat ttgtattcat cttccttcc 4860
 ttcttctctt ccttcttcc ttcttctctt ccttcttctc tcccttctt ccttcttcc 4920
 20 ttcttctctt ccttcttcc ttctgtgtc agagtgtga gaatcacacc tggggttccc 4980
 acccttatgt aaacaatctt ccagtggacc acagctcag tgcctgctggg tgcctctta 5040
 25 ccttctcac cccctggctt gtcctgttcc atctgggtca ggatctctag attggtctcc 5100
 cagcctctgc tactcctctt cctgctgtt cctctctctg tccagctgcg ccactgtggt 5160
 gcctcgttcc agctgtggtc cacattcttc aggattctct gaaaagttaa ccaggtgaga 5220
 30 atgtttcccc tgtagacagc agatcacgat tctcccgaa gtcaggcttc cagccctctc 5280
 tttctctgcc cagctgcccg gcaactctag caaacctcag gcacccttac ccacataga 5340
 cctctgacag agaagcaggc actttacatg gagtctgtg gggagagcca taggctacgg 5400
 35 tgtaaaagag gcaggggaagt ggtggtgtag gaaagtcagg acttcacata gaagcctagc 5460
 ccacaccaga aatgacagac agatccctcc tatctcccc ataagagttt gagtcgaggg 5520
 atctaagcag aagcttcgaa .tcgcgaattc gccacc atg ctg ctg ctg ctg ctg 5575
 40 Met Leu Leu Leu Leu Leu
 1 5
 ctg ctg ggc ctg agg cta cag ctc tcc ctg ggc atc atc cca gtt gag 5623
 Leu Leu Gly Leu Arg Leu Gln Leu Ser Leu Gly Ile Ile Pro Val Glu
 10 15 20
 45 gag gag aac ccg gac ttc tgg aac cgc gag gca gcc gag gcc ctg ggt 5671
 Glu Glu Asn Pro Asp Phe Trp Asn Arg Glu Ala Ala Glu Ala Leu Gly
 25 30 35
 gcc gcc aag aag ctg cag cct gca cag aca gcc gcc aag aac ctc atc 5719
 50 Ala Ala Lys Lys Leu Gln Pro Ala Gln Thr Ala Ala Lys Asn Leu Ile
 40 45 50
 atc ttc ctg ggc gat ggg atg ggg gtg tct acg gtg aca gct gcc agg 5767
 Ile Phe Leu Gly Asp Gly Met Gly Val Ser Thr Val Thr Ala Ala Arg
 55 60 65 70
 55 atc cta aaa ggg cag aag aag gac aaa ctg ggg cct gag ata ccc ctg 5815

EP 1 644 485 B9

	Ile	Leu	Lys	Gly	Gln	Lys	Lys	Asp	Lys	Leu	Gly	Pro	Glu	Ile	Pro	Leu	
					75					80					85		
5	gcc	atg	gac	cgc	ttc	cca	tat	gtg	gct	ctg	tcc	aag	aca	tac	aat	gta	5863
	Ala	Met	Asp	Arg	Phe	Pro	Tyr	Val	Ala	Leu	Ser	Lys	Thr	Tyr	Asn	Val	
				90					95					100			
10	gac	aaa	cat	gtg	cca	gac	agt	gga	gcc	aca	gcc	acg	gcc	tac	ctg	tgc	5911
	Asp	Lys	His	Val	Pro	Asp	Ser	Gly	Ala	Thr	Ala	Thr	Ala	Tyr	Leu	Cys	
			105					110					115				
15	ggg	gtc	aag	ggc	aac	ttc	cag	acc	att	ggc	ttg	agt	gca	gcc	gcc	cgc	5959
	Gly	Val	Lys	Gly	Asn	Phe	Gln	Thr	Ile	Gly	Leu	Ser	Ala	Ala	Ala	Arg	
		120					125					130					
20	ttt	aac	cag	tgc	aac	acg	aca	cgc	ggc	aac	gag	gtc	atc	tcc	gtg	atg	6007
	Phe	Asn	Gln	Cys	Asn	Thr	Thr	Arg	Gly	Asn	Glu	Val	Ile	Ser	Val	Met	
						140					145					150	
25	aat	cgg	gcc	aag	aaa	gca	ggg	aag	tca	gtg	gga	gtg	gta	acc	acc	aca	6055
	Asn	Arg	Ala	Lys	Lys	Ala	Gly	Lys	Ser	Val	Gly	Val	Val	Thr	Thr	Thr	
					155					160					165		
30	cga	gtg	cag	cac	gcc	tcg	cca	gcc	ggc	acc	tac	gcc	cac	acg	gtg	aac	6103
	Arg	Val	Gln	His	Ala	Ser	Pro	Ala	Gly	Thr	Tyr	Ala	His	Thr	Val	Asn	
				170					175					180			
35	cgc	aac	tgg	tac	tcg	gac	gcc	gac	gtg	cct	gcc	tcg	gcc	cgc	cag	gag	6151
	Arg	Asn	Trp	Tyr	Ser	Asp	Ala	Asp	Val	Pro	Ala	Ser	Ala	Arg	Gln	Glu	
			185				190						195				
40	ggg	tgc	cag	gac	atc	gct	acg	cag	ctc	atc	tcc	aac	atg	gac	att	gac	6199
	Gly	Cys	Gln	Asp	Ile	Ala	Thr	Gln	Leu	Ile	Ser	Asn	Met	Asp	Ile	Asp	
			200				205					210					
45	gtg	atc	cta	ggt	gga	ggc	cga	aag	tac	atg	ttt	cgc	atg	gga	acc	cca	6247
	Val	Ile	Leu	Gly	Gly	Gly	Arg	Lys	Tyr	Met	Phe	Arg	Met	Gly	Thr	Pro	
			215			220					225					230	
50	gac	cct	gag	tac	cca	gat	gac	tac	agc	caa	ggt	ggg	acc	agg	ctg	gac	6295
	Asp	Pro	Glu	Tyr	Pro	Asp	Asp	Tyr	Ser	Gln	Gly	Gly	Thr	Arg	Leu	Asp	
					235					240					245		
55	ggg	aag	aat	ctg	gtg	cag	gaa	tgg	ctg	gcg	aag	cgc	cag	ggt	gcc	cgg	6343
	Gly	Lys	Asn	Leu	Val	Gln	Glu	Trp	Leu	Ala	Lys	Arg	Gln	Gly	Ala	Arg	
				250				255						260			
60	tat	gtg	tgg	aac	cgc	act	gag	ctc	atg	cag	gct	tcc	ctg	gac	cgc	tct	6391
	Tyr	Val	Trp	Asn	Arg	Thr	Glu	Leu	Met	Gln	Ala	Ser	Leu	Asp	Pro	Ser	
			265				270						275				
65	gtg	acc	cat	ctc	atg	ggt	ctc	ttt	gag	cct	gga	gac	atg	aaa	tac	gag	6439
	Val	Thr	His	Leu	Met	Gly	Leu	Phe	Glu	Pro	Gly	Asp	Met	Lys	Tyr	Glu	
			280				285					290					
70	atc	cac	cga	gac	tcc	aca	ctg	gac	ccc	tcc	ctg	atg	gag	atg	aca	gag	6487
	Ile	His	Arg	Asp	Ser	Thr	Leu	Asp	Pro	Ser	Leu	Met	Glu	Met	Thr	Glu	
			295			300					305					310	
75	gct	gcc	ctg	cgc	ctg	ctg	agc	agg	aac	ccc	cgc	ggc	ttc	ttc	ctc	ttc	6535
	Ala	Ala	Leu	Arg	Leu	Leu	Ser	Arg	Asn	Pro	Arg	Gly	Phe	Phe	Leu	Phe	
					315					320					325		

EP 1 644 485 B9

	gtg gag ggt ggt cgc atc gac cat ggt cat cat gaa agc agg gct tac	6583
	Val Glu Gly Gly Arg Ile Asp His Gly His His Glu Ser Arg Ala Tyr	
	330 335 340	
5	cgg gca ctg act gag acg atc atg ttc gac gac gcc att gag agg gcg	6631
	Arg Ala Leu Thr Glu Thr Ile Met Phe Asp Asp Ala Ile Glu Arg Ala	
	345 350 355	
10	ggc cag ctc acc agc gag gag gac acg ctg agc ctc gtc act gcc gac	6679
	Gly Gln Leu Thr Ser Glu Glu Asp Thr Leu Ser Leu Val Thr Ala Asp	
	360 365 370	
15	cac tcc cac gtc ttc tcc ttc gga ggc tac ccc ctg cga ggg agc tcc	6727
	His Ser His Val Phe Ser Phe Gly Gly Tyr Pro Leu Arg Gly Ser Ser	
	375 380 385 390	
20	atc ttc ggg ctg gcc cct ggc aag gcc cgg gac agg aag gcc tac acg	6775
	Ile Phe Gly Leu Ala Pro Gly Lys Ala Arg Asp Arg Lys Ala Tyr Thr	
	395 400 405	
25	gtc ctc cta tac gga aac ggt cca ggc tat gtg ctc aag gac ggc gcc	6823
	Val Leu Leu Tyr Gly Asn Gly Pro Gly Tyr Val Leu Lys Asp Gly Ala	
	410 415 420	
30	cgg ccg gat gtt acc gag agc gag agc ggg agc ccc gag tat cgg cag	6871
	Arg Pro Asp Val Thr Glu Ser Glu Ser Gly Ser Pro Glu Tyr Arg Gln	
	425 430 435	
35	cag tca gca gtg ccc ctg gac gaa gag acc cac gca ggc gag gac gtg	6919
	Gln Ser Ala Val Pro Leu Asp Glu Glu Thr His Ala Gly Glu Asp Val	
	440 445 450	
40	gcg gtg ttc gcg cgc ggc ccg cag gcg cac ctg gtt cac ggc gtg cag	6967
	Ala Val Phe Ala Arg Gly Pro Gln Ala His Leu Val His Gly Val Gln	
	455 460 465 470	
45	gag cag acc ttc ata gcg cac gtc atg gcc ttc gcc gcc tgc ctg gag	7015
	Glu Gln Thr Phe Ile Ala His Val Met Ala Phe Ala Ala Cys Leu Glu	
	475 480 485	
50	ccc tac acc gcc tgc gac ctg gcg ccc ccc gcc ggc acc acc gac gcc	7063
	Pro Tyr Thr Ala Cys Asp Leu Ala Pro Pro Ala Gly Thr Thr Asp Ala	
	490 495 500	
55	gcg cac ccg ggt tac tct aga gtc ggg gcg gcc ggc cgc ttc gag cag	7111
	Ala His Pro Gly Tyr Ser Arg Val Gly Ala Ala Gly Arg Phe Glu Gln	
	505 510 515	
60	aca tga taagatacat tgatgagttt ggacgcggcc gcgactctag atcataatca	7167
	Thr	
65	gccataccac attttagtag gttttacttg ctttaaaaaa cctccacac ctccccctga	7227
70	acctgaaaca taaaatgaat gcaattgttg ttgttaactt gtttattgca gcttataatg	7287
75	gttacaaata aagcaatagc atcaciaaatt tcacaaataa agcatttttt tcaactgcatt	7347
80	ctagttgtgg tttgtccaaa ctcatcaatg tatcttaagg cgtaaattgt aagcgttaat	7407
85	atittgttaa aattcgcggt aaatttttgt taaatcagct cattttttta ccaataggcc	7467
90	gaaatcggca aaatccctta taaatcaaaa gaatagaccg agatagggtt gagtgttggt	7527

EP 1 644 485 B9

ccagtttggg acaagagtcc actattaag aacgtggact ccaacgtcaa agggcgaaaa 7587
 accgtctatc agggcgatgg cccactacgt gaaccatcac cctaatcaag ttttttgggg 7647
 5 tcgaggtgcc gtaaagcact aaatcggaac cctaaaggga gcccccgatt tagagcttga 7707
 cggggaaaag cggcgaaact ggcgagaaaag gaagggaaga aagcgaaag agcgggcgct 7767
 agggcgctgg caagtgtagc ggtcacgctg cgcgtaacca ccacaccgc cgcgcttaat 7827
 10 gcgcccctac agggcgctc aggtggcact tttcggggaa atgtgcgctg aaccctatt 7887
 tgtttatttt tctaaataca ttcaaatatg tatccgctca tgagacaata accctgataa 7947
 atgcttcaat aatattgaaa aaggaagagt cctgagggcg aaagaaccag ctgtggaatg 8007
 15 tgtgtcagtt aggggtgtga aagtccccag gctccccagc aggcagaagt atgcaaagca 8067
 tgcattctca ttagtcagca accaggtgtg gaaagtcccc aggtccccca gcaggcagaa 8127
 20 gtatgcaaag catgcatctc aattagtcag caaccatagt cccgccccta actccgccc 8187
 tcccgcccct aactccgccc agttccgccc atttccgccc ccatggctga ctaatttttt 8247
 ttatttatgc agaggccgag gccgcctcgg cctctgagct attccagaag tagtgaggag 8307
 25 gcttttttgg aggcctaggc ttttgcaaag atcgatcaag agacaggatg aggatcgttt 8367
 cgcatgattg aacaagatgg attgcacgca ggttctccgg ccgcttggtt ggagaggcta 8427
 ttcggctatg actgggcaca acagacaatc ggctgctctg atgccgctg gttccggctg 8487
 30 tcagcgagg ggcgcccgt tctttttgtc aagaccgacc tgtccggtgc cctgaatgaa 8547
 ctgcaagacg aggcagcgcg gctatcgtgg ctggccacga cggcgcttcc ttgcgagct 8607
 gtgctcgacg ttgtcactga agcgggaagg gactggctgc tattgggca agtgccgggg 8667
 35 caggatctcc tgtcatctca ccttgctcct gccgagaaag tatccatcat ggctgatgca 8727
 atgcggcggc tgcatacgtc tgatccggct acctgccat tcgaccacca agcgaacat 8787
 cgcacgagc gagcacgtac tcggatggaa gccggtcttg tcgatcagga tgatctggac 8847
 40 gaagagcatc aggggctcgc gccagccgaa ctgttcgcca ggctcaaggc gagcatgccc 8907
 gacggcgagg atctcgtcgt gacccatggc gatgcctgct tgccgaatat catggtggaa 8967
 45 aatggcogct tttctggatt catcgactgt ggccggctgg gtgtggcgga ccgctatcag 9027
 gacatagcgt tggctaccgc tgatattgct gaagagcttg gcggcgaatg ggctgaccgc 9087
 ttctcgtgc tttacggtat cgcgctccc gattcgcagc gcacgcctt ctatgcctt 9147
 50 cttgacgagt tcttctgagc gggactctgg ggttcgaaat gaccgaccaa gcgacgccc 9207
 acctgccatc acgagattc gattccaccg ccgccttcta tgaaaggttg ggcttcggaa 9267
 tcgttttccg ggacgccggc tggatgatcc tccagcgcgg ggatctcatg ctggagttct 9327
 55 tcgcccacc tagggggagg ctaactgaaa cacggaagga gacaataccg gaaggaacc 9387

EP 1 644 485 B9

gcgctatgac ggcaataaaa agacagaata aaacgcacgg tgttggtcg tttgttcata 9447
 aacgcgggggt tccgtcccag ggctggcact ctgtcgatac cccaccgaga cccattggg 9507
 5 gccaatacgc ccgcgtttct tccttttccc caccaccacc cccaagtctg ggtgaaggcc 9567
 cagggctcgc agccaacgtc gggcgggcag gccctgccat agcctcaggt tactcatata 9627
 10 tacttttagat tgatttaaaa cttcattttt aattttaaag gatctaggtg aagatccttt 9687
 ttgataatct catgacaaa atcccttaac gtgagttttc gttccactga gcgtcagacc 9747
 ccgtagaaaa gatcaaagga tcttcttgag atcctttttt tctgcgcgta atctgctgct 9807
 15 tgcaaacaaa aaaaccaccg ctaccagcgg tggtttgttt gccggatcaa gagctaccaa 9867
 ctctttttcc gaaggttaact ggcttcagca gagcgcagat accaaatact gtccttctag 9927
 tgtagccgta gttaggccac cacttcaaga actctgtagc accgcctaca tacctcgctc 9987
 20 tgctaatacct gttaccagtg gctgctgcca gtggcgataa gtcgtgtctt accggggttg 10047
 actcaagacg atagttaccg gataaggcgc agcggtcggg ctgaacgggg ggttcgtgca 10107
 25 cacagcccag cttggagcga acgacctaca ccgaactgag atacctacag cgtgagctat 10167
 gagaaagcgc cacgcttccc gaaggagaa aggcggacag gtatccggta agcggcaggg 10227
 tcggaacagg agagcgcacg agggagcttc cagggggaaa cgcttggtat ctttatagtc 10287
 30 ctgtcggggt tcgccacctc tgacttgagc gtcgattttt gtgatgctcg tcaggggggc 10347
 ggagcctatg gaaaaacgcc agcaacgcgg cctttttacg gttcctggcc ttttgctggc 10407
 35 cttttgctca catgttcttt cctgcgttat cccctgattc tgtggataac cgtattaccg 10467
 ccatgcat 10475

40 <210> 4
 <211> 519
 <212> PRT
 <213> SEAP

45 <400> 4

Met Leu Leu Leu Leu Leu Leu Leu Gly Leu Arg Leu Gln Leu Ser Leu
 1 5 10 15
 50 Gly Ile Ile Pro Val Glu Glu Glu Asn Pro Asp Phe Trp Asn Arg Glu
 20 25 30
 55 Ala Ala Glu Ala Leu Gly Ala Ala Lys Lys Leu Gln Pro Ala Gln Thr
 35 40 45

EP 1 644 485 B9

Ala Ala Lys Asn Leu Ile Ile Phe Leu Gly Asp Gly Met Gly Val Ser
50 55 60

5 Thr Val Thr Ala Ala Arg Ile Leu Lys Gly Gln Lys Lys Asp Lys Leu
65 70 75 80

10 Gly Pro Glu Ile Pro Leu Ala Met Asp Arg Phe Pro Tyr Val Ala Leu
85 90 95

15 Ser Lys Thr Tyr Asn Val Asp Lys His Val Pro Asp Ser Gly Ala Thr
100 105 110

Ala Thr Ala Tyr Leu Cys Gly Val Lys Gly Asn Phe Gln Thr Ile Gly
115 120 125

20 Leu Ser Ala Ala Ala Arg Phe Asn Gln Cys Asn Thr Thr Arg Gly Asn
130 135 140

25 Glu Val Ile Ser Val Met Asn Arg Ala Lys Lys Ala Gly Lys Ser Val
145 150 155 160

Gly Val Val Thr Thr Thr Arg Val Gln His Ala Ser Pro Ala Gly Thr
165 170 175

30 Tyr Ala His Thr Val Asn Arg Asn Trp Tyr Ser Asp Ala Asp Val Pro
180 185 190

35 Ala Ser Ala Arg Gln Glu Gly Cys Gln Asp Ile Ala Thr Gln Leu Ile
195 200 205

Ser Asn Met Asp Ile Asp Val Ile Leu Gly Gly Gly Arg Lys Tyr Met
210 215 220

40 Phe Arg Met Gly Thr Pro Asp Pro Glu Tyr Pro Asp Asp Tyr Ser Gln
225 230 235 240

45 Gly Gly Thr Arg Leu Asp Gly Lys Asn Leu Val Gln Glu Trp Leu Ala
245 250 255

Lys Arg Gln Gly Ala Arg Tyr Val Trp Asn Arg Thr Glu Leu Met Gln
260 265 270

50 Ala Ser Leu Asp Pro Ser Val Thr His Leu Met Gly Leu Phe Glu Pro
275 280 285

55 Gly Asp Met Lys Tyr Glu Ile His Arg Asp Ser Thr Leu Asp Pro Ser
290 295 300

EP 1 644 485 B9

5
 Leu Met Glu Met Thr Glu Ala Ala Leu Arg Leu Leu Ser Arg Asn Pro
 305 310 315 320

10
 Arg Gly Phe Phe Leu Phe Val Glu Gly Gly Arg Ile Asp His Gly His
 325 330 335

15
 His Glu Ser Arg Ala Tyr Arg Ala Leu Thr Glu Thr Ile Met Phe Asp
 340 345 350

20
 Asp Ala Ile Glu Arg Ala Gly Gln Leu Thr Ser Glu Glu Asp Thr Leu
 355 360 365

25
 Ser Leu Val Thr Ala Asp His Ser His Val Phe Ser Phe Gly Gly Tyr
 370 375 380

30
 Pro Leu Arg Gly Ser Ser Ile Phe Gly Leu Ala Pro Gly Lys Ala Arg
 385 390 395 400

35
 Asp Arg Lys Ala Tyr Thr Val Leu Leu Tyr Gly Asn Gly Pro Gly Tyr
 405 410 415

40
 Val Leu Lys Asp Gly Ala Arg Pro Asp Val Thr Glu Ser Glu Ser Gly
 420 425 430

45
 Ser Pro Glu Tyr Arg Gln Gln Ser Ala Val Pro Leu Asp Glu Glu Thr
 435 440 445

50
 His Ala Gly Glu Asp Val Ala Val Phe Ala Arg Gly Pro Gln Ala His
 450 455 460

55
 Leu Val His Gly Val Gln Glu Gln Thr Phe Ile Ala His Val Met Ala
 465 470 475 480

60
 Phe Ala Ala Cys Leu Glu Pro Tyr Thr Ala Cys Asp Leu Ala Pro Pro
 485 490 495

65
 Ala Gly Thr Thr Asp Ala Ala His Pro Gly Tyr Ser Arg Val Gly Ala
 500 505 510

70
 Ala Gly Arg Phe Glu Gln Thr
 515

Claims

1. A method of monitoring cell differentiation comprising:
 - 5 (a) culturing cells capable of differentiating into at least one particular cell type containing at least one recombinant nucleic acid molecule comprising a reporter gene encoding a product that is secreted upon cell differentiation, or maintaining a non-human animal comprising such cells, under conditions allowing differentiation of the cells; and
 - 10 (b) quantifying the differentiated cells by determining the amount or activity of the reporter gene product either within a body fluid of said transgenic non-human animal or the cell culture medium.
2. The method of claim 1, wherein said recombinant nucleic acid molecule comprises at least one cell type-specific regulatory sequence operably linked to said reporter gene.
- 15 3. The method of claim 1 or 2, wherein said cells are or are derived from stem cells.
4. The method of claim 3, wherein said stem cells are cells of an embryonic stem cell line or multipotent adult progenitor cells (MAPCs).
- 20 5. The method of any one of claims 1 to 4, wherein said reporter gene product comprises a secretory leader sequence.
6. The method of any one of claims 2 to 5, wherein said regulatory sequence comprises a promoter and/or enhancer element.
- 25 7. The method of any one of claims 1 to 6, wherein said cell type is selected from the group consisting of connecting fibroblasts, stromal cells, endothelial cells, glial cells, neural cells, neuronal cells, hematopoietic cells, smooth muscle cells, skeletal muscle cells, epithelial cells, and cardiac cells.
- 30 8. The method of claim 6 or 7, wherein said promoter or enhancer is selected from the group consisting of aMHC, MLC2V, VE-cadherin, Tie-2, Flk-1, Flt-1, GFAP, alpha-1-tubulin and collagen 2 promoter or enhancer.
9. The method of any of claims 1 to 8, wherein said reporter gene product is secreted alkaline phosphatase (SEAP) or alpha-amylase.
- 35 10. The method of any one of claims 1 to 9, wherein said recombinant nucleic acid molecule further comprises a selectable marker expressed by multi- or pluripotent cells.
11. The method of any one of claims 1 to 10, wherein said cells form cell aggregates or tissue-like aggregates derived from different cell types.
- 40 12. The method of any one of claims 1 to 11, wherein said cells form embryoid bodies (EBs).
13. A reporter gene construct for monitoring cell differentiation by quantifying the differentiated cells comprising a recombinant nucleic acid molecule as defined in any one of claims 1, 2, 5, 6 or 8 to 10.
- 45 14. A cell comprising a reporter gene construct of claim 13, wherein said cell is capable of differentiating into at least one particular cell type.
15. A cell aggregate of at least one cell type comprising cells of claim 14.
- 50 16. A tissue comprising cells of claim 14 or a cell aggregate of claim 15.
17. An organ comprising a tissue of claim 16, a cell of claim 14 or a cell aggregate of claim 15.
- 55 18. An implant or transplant comprising an organ of claim 17, a tissue of claim 16, a cell of claim 14 or a cell aggregate of claim 15.
19. A non-human animal comprising a reporter gene construct of claim 13, a cell of claim 14, a cell aggregate of claim

15, a tissue of claim 16 or an organ of claim 17.

20. A composition of matter comprising a reporter gene construct of claim 13, a tissue of claim 16, cells of claim 14 or a cell aggregate of claim 15.

5

21. An array comprising a solid support and attached thereto or suspended thereon cells of claim 14, a cell aggregate of claim 15 or a tissue of claim 16.

10

22. Use of an apparatus for analyzing the array of claim 21.

23. A method of obtaining and/or profiling a modulator of cell differentiation comprising:

(a) contacting a test sample comprising a cell of claim 14, a cell aggregate of claim 15, a tissue of claim 16 or an organ of claim 17 or a non-human animal of claim 19 with a test substance; and

15

(b) determining the effect of the test substance on the amount of the reporter gene product or activity compared to a control sample or animal.

24. The method of any one of claims 1 to 12 or 23, wherein a compound known to activate or inhibit the differentiation process is added to the culture medium or animal.

20

25. The method of any one of claims 23 or 24, wherein the test substance is a therapeutic agent, or a mixture of therapeutic agents.

26. The method of any one of claims 23 to 25, which is performed on an array.

25

27. The method of any one of claims 1 to 12 or 23 to 26, wherein said one or more cells are genetically engineered to (over)express or inhibit the expression of a target gene.

28. A kit useful for conducting a method of any one of claims 1 to 12 or 23 to 27, containing a reporter gene construct of claim 13 or a cell of claim 14, and optionally standard compounds, like cell culture media, selection agents, detection agents for the reporter molecule and control samples.

30

29. Use of a reporter gene construct of claim 13, a cell of claim 14, a cell aggregate of claim 15, a tissue of claim 16, an organ of claim 17, the implant or transplant of claim 18, a non-human animal of claim 19, the composition of claim 20 or an array of claim 21 in drug discovery or pharmacokinetic or pharmacological profiling.

35

30. A vector comprising the promoter region of the mouse alpha myosin heavy chain gene or of the ventricular myosin regulatory light chain gene, and operably linked thereto a 5 heterologous DNA sequence, which encodes secreted alkaline phosphatase protein (SEAP).

40

31. The vector of claim 30, wherein said promoter comprises the nucleotide sequence of SEQ ID NO: 1 or 2, or a fragment thereof.

32. The vector of claim 30 or 31 comprising the nucleotide sequence of SEQ ID NO: 3.

45

33. Use of a promoter region of the mouse alpha myosin heavy chain gene or of the ventricular myosin regulatory light chain gene for the specific expression of heterologous DNA sequences during embryogenesis or cell development in a method of any one of claims 1 to 12 or 23 to 27.

50

Patentansprüche

1. Verfahren zur Überwachung der Zelldifferenzierung umfassend:

55

(a) das Kultivieren von Zellen, die dazu in der Lage sind, zu mindestens einem bestimmten Zelltyp zu differenzieren, der mindestens ein rekombinantes Nukleinsäuremolekül enthält, das ein Reportergen umfasst, das für ein Produkt kodiert, das bei der Zelldifferenzierung sezerniert wird, oder die Aufrechterhaltung eines nicht humanen Tiers, das solche Zellen umfasst, unter Bedingungen, die eine Differenzierung der Zellen gestatten;

EP 1 644 485 B9

und

(b) das Quantifizieren der differenzierten Zellen durch Bestimmen der Menge oder der Aktivität des Reporter-
genprodukts entweder in einer Körperflüssigkeit des transgenen nicht humanen Tiers oder im Zellkulturmedium.

- 5 2. Verfahren nach Anspruch 1, wobei das rekombinante Nukleinsäuremolekül mindestens eine für den Zelltyp spezifische regulatorische Sequenz umfasst, die funktionell mit dem Reporter-
gen verknüpft ist.
3. Verfahren nach Anspruch 1 oder 2, wobei die Zellen Stammzellen oder von Stammzellen abgeleitete Zellen sind.
- 10 4. Verfahren nach Anspruch 3, wobei die Stammzellen Zellen aus einer embryonalen Stammzelllinie oder multipotente adulte Progenitorzellen (MAPC) sind.
5. Verfahren nach einem der Ansprüche 1 bis 4, wobei das Reporter-
genprodukt eine sekretorische Leadersequenz umfasst.
- 15 6. Verfahren nach einem der Ansprüche 2 bis 5, wobei die regulatorische Sequenz ein Promotor- und/oder ein Enhancerelement umfasst.
- 20 7. Verfahren nach einem der Ansprüche 1 bis 6, wobei der Zelltyp ausgewählt ist aus der Gruppe bestehend aus Bindegewebsfibroblasten, Stromazellen, Endothelzellen, Gliazellen, neuronalen Zellen, hämatopoetischen Zellen, glatten Muskelzellen, Skelettmuskelzellen, Epithelzellen und kardialen Zellen.
- 25 8. Verfahren nach Anspruch 6 oder 7, wobei der Promotor oder Enhancer ausgewählt ist aus der Gruppe bestehend aus einem aMHC-, MLC2V-, VE-Cadherin-, Tie-2-, Flk-1-, Flt-1-, GFAP-, alpha-1-Tubulin- und Collagen 2-Promotor oder Enhancer.
9. Verfahren nach einem der Ansprüche 1 bis 8, wobei das Reporter-
genprodukt sezernierte alkalische Phosphatase (SEAP) oder alpha-Amylase ist.
- 30 10. Verfahren nach einem der Ansprüche 1 bis 9, wobei das rekombinante Nukleinsäuremolekül des Weiteren einen selektierbaren Marker umfasst, der durch multi- oder pluripotente Zellen exprimiert wird.
- 35 11. Verfahren nach einem der Ansprüche 1 bis 10, wobei die Zellen Zellaggregate oder gewebeähnliche Aggregate bilden, die von unterschiedlichen Zelltypen abgeleitet sind.
- 40 12. Verfahren nach einem der Ansprüche 1 bis 11, wobei die Zellen Embryoidkörper (EB) bilden.
13. Reporter-
genkonstrukt zur Überwachung der Zelldifferenzierung durch Quantifizieren der differenzierten Zellen, umfassend ein rekombinantes Nukleinsäuremolekül wie in einem der Ansprüche 1, 2, 5, 6 oder 8 bis 10 definiert.
- 45 14. Zelle umfassend ein Reporter-
genkonstrukt nach Anspruch 13, wobei die Zelle dazu in der Lage ist, zu mindestens einem bestimmten Zelltyp zu differenzieren.
15. Zellaggregat mindestens eines Zelltyps umfassend Zellen nach Anspruch 14.
- 50 16. Gewebe umfassend Zellen nach Anspruch 14 oder ein Zellaggregat nach Anspruch 15.
17. Organ umfassend ein Gewebe nach Anspruch 16, eine Zelle nach Anspruch 14 oder ein Zellaggregat nach Anspruch 15.
- 55 18. Implantat oder Transplantat umfassend ein Organ nach Anspruch 17, ein Gewebe nach Anspruch 16, eine Zelle nach Anspruch 14 oder ein Zellaggregat nach Anspruch 15.
19. Nicht humanes Tier umfassend ein Reporter-
genkonstrukt nach Anspruch 13, eine Zelle nach Anspruch 14, ein Zellaggregat nach Anspruch 15, ein Gewebe nach Anspruch 16 oder ein Organ nach Anspruch 17.
20. Stoffzusammensetzung umfassend ein Reporter-
genkonstrukt nach Anspruch 13, ein Gewebe nach Anspruch 16, Zellen nach Anspruch 14 oder ein Zellaggregat nach Anspruch 15.

EP 1 644 485 B9

21. Array umfassend einen festen Träger und entweder daran befestigt oder darauf suspendiert Zellen nach Anspruch 14, ein Zellaggregat nach Anspruch 15 oder ein Gewebe nach Anspruch 16.
22. Verwendung einer Vorrichtung zur Analyse des Arrays nach Anspruch 21.
23. Verfahren zum Erhalt und/oder zur Profilierung eines Modulators der Zelldifferenzierung, umfassend:
- (a) Inkontaktbringen einer Testprobe umfassend eine Zelle nach Anspruch 14, ein Zellaggregat nach Anspruch 15, ein Gewebe nach Anspruch 16 oder ein Organ nach Anspruch 17 oder ein nicht humanes Tier nach Anspruch 19 mit einer Testsubstanz; und
 - (b) Bestimmen der Wirkung der Testsubstanz auf die Menge an Reporterprodukt oder die Aktivität im Vergleich zu einer Kontrollprobe oder einem Kontrolltier.
24. Verfahren nach einem der Ansprüche 1 bis 12 oder 23, wobei eine Verbindung, von der bekannt ist, dass sie den Differenzierungsprozess aktiviert oder inhibiert, zu dem Kulturmedium oder dem Tier gegeben wird.
25. Verfahren nach einem der Ansprüche 23 oder 24, wobei die Testsubstanz ein therapeutischer Wirkstoff oder ein Gemisch von therapeutischen Wirkstoffen ist.
26. Verfahren nach einem der Ansprüche 23 bis 25, das auf einem Array durchgeführt wird.
27. Verfahren nach einem der Ansprüche 1 bis 12 oder 23 bis 26, wobei die eine oder die mehreren Zellen gentechnisch verändert wird bzw. werden, um ein Zielgen zu (über-) exprimieren oder die Expression eines Zielgens zu inhibieren.
28. Kit, das zweckmäßig für die Durchführung eines Verfahrens nach einem der Ansprüche 1 bis 12 oder 23 bis 27 ist, enthaltend ein Reportergenkonstrukt nach Anspruch 13 oder eine Zelle nach Anspruch 14 sowie gegebenenfalls Standardverbindungen wie Zellkulturmedien, Agenzien zur Selektionierung, Agenzien zur Detektion des Reporter-moleküls und Kontrollproben.
29. Verwendung eines Reportergenkonstrukts nach Anspruch 13, einer Zelle nach Anspruch 14, eines Zellaggregats nach Anspruch 15, eines Gewebes nach Anspruch 16, eines Organs nach Anspruch 17, des Implantats oder Transplantats nach Anspruch 18, eines nicht humanen Tiers nach Anspruch 19, der Zusammensetzung nach Anspruch 20 oder eines Arrays nach Anspruch 21 in der Arzneimittelforschung oder der pharmakokinetischen oder pharmakologischen Profilierung.
30. Vektor umfassend die Promotorregion des murinen Gens für die schwere Kette von alpha-Myosin oder des Gens für die regulatorische leichte Kette von ventrikulärem Myosin, sowie funktionell mit dieser verknüpft eine heterologe DNA-Sequenz, die für das Protein der sezernierten alkalischen Phosphatase (SEAP) kodiert.
31. Vektor nach Anspruch 30, wobei der Promotor die Nukleotidsequenz gemäß SEQ ID NR: 1 oder 2 oder ein Fragment davon umfasst.
32. Vektor nach Anspruch 30 oder 31 umfassend die Nukleotidsequenz gemäß SEQ ID NR: 3.
33. Verwendung einer Promotorregion des murinen Gens für die schwere Kette von alpha-Myosin oder des Gens für die regulatorische leichte Kette von ventrikulärem Myosin für die spezifische Expression von heterologen DNA-Sequenzen während der Embryogenese oder der Zellentwicklung in einem Verfahren nach einem der Ansprüche 1 bis 12 oder 23 bis 27.

Revendications

1. Procédé pour contrôler la différenciation de cellules comprenant :
- (a) la mise en culture de cellules aptes à se différencier en au moins un type cellulaire particulier contenant au moins une molécule d'acide nucléique recombinante comprenant un gène rapporteur codant un produit qui est sécrété lors de la différenciation des cellules, ou l'entretien d'un animal non humain comprenant de telles cellules, dans des conditions permettant la différenciation des cellules ; et

EP 1 644 485 B9

(b) la quantification des cellules différenciées par détermination de la quantité ou de l'activité du produit du gène rapporteur soit dans un fluide corporel dudit animal non humain transgénique soit dans le milieu de culture des cellules.

- 5 2. Procédé selon la revendication 1, dans lequel ladite molécule d'acide nucléique recombinante comprend au moins une séquence régulatrice spécifique d'un type cellulaire fonctionnellement liée audit gène rapporteur.
3. Procédé selon la revendication 1 ou 2, dans lequel lesdites cellules sont des cellules souches ou dérivent de cellules souches.
- 10 4. Procédé selon la revendication 3, dans lequel lesdites cellules souches sont des cellules d'une lignée de cellules souches embryonnaires ou des cellules progénitrices adultes multipotentes (MAPC).
- 15 5. Procédé selon l'une quelconque des revendications 1 à 4, dans lequel ledit produit du gène rapporteur comprend une séquence de tête sécrétoire.
6. Procédé selon l'une quelconque des revendications 2 à 5, dans lequel ladite séquence régulatrice comprend un élément promoteur et/ou activateur.
- 20 7. Procédé selon l'une quelconque des revendications 1 à 6, dans lequel ledit type cellulaire est choisi dans le groupe constitué des fibroblastes du tissu conjonctif, des cellules stromales, des cellules endothéliales, des cellules gliales, des cellules neurales, des cellules neuronales, des cellules hématopoïétiques, des cellules du muscle lisse, des cellules du muscle squelettique, des cellules épithéliales, et des cellules cardiaques.
- 25 8. Procédé selon la revendication 6 ou 7, dans lequel ledit promoteur ou activateur est choisi dans le groupe constitué du promoteur ou de l'activateur de aMHC, de MLC2V, de VE-cadhérine, de Tie-2, de Flk-1, de Flt-1, de GFAP, de l'alpha-1-tubuline et du collagène de type 2.
- 30 9. Procédé selon l'une quelconque des revendications 1 à 8, dans lequel ledit produit du gène rapporteur est la phosphatase alcaline sécrétée (SEAP) ou l'alpha-amylase.
10. Procédé selon l'une quelconque des revendications 1 à 9, dans lequel ladite molécule d'acide nucléique recombinante comprend en outre un marqueur de sélection exprimé par des cellules multi- ou pluripotentes.
- 35 11. Procédé selon l'une quelconque des revendications 1 à 10, dans lequel lesdites cellules forment des agrégats cellulaires ou des agrégats d'aspect tissulaire issus de différents types cellulaires.
- 40 12. Procédé selon l'une quelconque des revendications 1 à 11, dans lequel lesdites cellules forment des corps embryoides (EB).
13. Construction de gène rapporteur servant à contrôler la différenciation de cellules par quantification des cellules différenciées comprenant une molécule d'acide nucléique recombinante telle que définie dans l'une quelconque des revendications 1, 2, 5, 6 ou 8 à 10.
- 45 14. Cellule comprenant une construction de gène rapporteur selon la revendication 13, où ladite cellule est apte à se différencier en au moins un type cellulaire particulier.
15. Agrégat cellulaire d'au moins un type cellulaire comprenant des cellules selon la revendication 14.
- 50 16. Tissu comprenant des cellules selon la revendication 14 ou un agrégat cellulaire selon la revendication 15.
17. Organe comprenant un tissu selon la revendication 16, une cellule selon la revendication 14, ou un agrégat cellulaire selon la revendication 15.
- 55 18. Implant ou transplant comprenant un organe selon la revendication 17, un tissu selon la revendication 16, une cellule selon la revendication 14 ou un agrégat cellulaire selon la revendication 15.
19. Animal non humain comprenant une construction de gène rapporteur selon la revendication 13, une cellule selon

EP 1 644 485 B9

la revendication 14, un agrégat cellulaire selon la revendication 15, un tissu selon la revendication 16 ou un organe selon la revendication 17.

- 5 **20.** Composition de matière comprenant une construction de gène rapporteur selon la revendication 13, un tissu selon la revendication 16, des cellules selon la revendication 14 ou un agrégat cellulaire selon la revendication 15.
- 10 **21.** Puce comprenant un support solide et, fixées à celui-ci ou en suspension sur celui-ci, des cellules selon la revendication 14, un agrégat cellulaire selon la revendication 15, ou un tissu selon la revendication 16.
- 15 **22.** Utilisation d'un appareil pour analyser la puce selon la revendication 21.
- 20 **23.** Procédé d'obtention et/ou de profilage d'un modulateur de la différenciation cellulaire, comprenant :
- 25 (a) la mise en contact d'un échantillon d'essai comprenant une cellule selon la revendication 14, un agrégat cellulaire selon la revendication 15, un tissu selon la revendication 16, un organe selon la revendication 17 ou un animal non humain selon la revendication 19, avec une substance à tester ; et
- 30 (b) la détermination de l'effet de la substance à tester sur la quantité du produit du gène rapporteur ou le niveau d'activité de celui-ci par rapport à un échantillon ou animal témoin.
- 35 **24.** Procédé selon l'une quelconque des revendications 1 à 12 ou 23, dans lequel un composé connu pour activer ou inhiber le processus de différenciation est ajouté au milieu de culture ou à l'animal.
- 40 **25.** Procédé selon l'une quelconque des revendications 23 ou 24, dans lequel la substance à tester est un agent thérapeutique, ou un mélange d'agents thérapeutiques.
- 45 **26.** Procédé selon l'une quelconque des revendications 23 à 25, qui est mis en oeuvre sur une puce.
- 50 **27.** Procédé selon l'une quelconque des revendications 1 à 12 ou 23 à 26, dans lequel ladite/lesdites une ou plusieurs cellule(s) est/sont génétiquement manipulée(s) pour (sur)exprimer ou inhiber l'expression d'un gène cible.
- 55 **28.** Kit utile pour mettre en oeuvre un procédé selon l'une quelconque des revendications 1 à 12 ou 23 à 27, contenant une construction de gène rapporteur selon la revendication 13 ou une cellule selon la revendication 14, et, facultativement, des composés standard tels que des milieux de culture cellulaire, des agents de sélection, des agents de détection pour la molécule rapporteur et des échantillons témoins.
- 60 **29.** Utilisation d'une construction de gène rapporteur selon la revendication 13, d'une cellule selon la revendication 14, d'un agrégat cellulaire selon la revendication 15, d'un tissu selon la revendication 16, d'un organe selon la revendication 17, de l'implant ou du transplant selon la revendication 18, d'un animal non humain selon la revendication 19, de la composition selon la revendication 20 ou d'une puce selon la revendication 21, dans le cadre de la découverte de médicaments ou de l'établissement de profils pharmacocinétiques ou pharmacologiques.
- 65 **30.** Vecteur comprenant la région promotrice du gène de la chaîne lourde alpha de la myosine murine ou du gène de la chaîne légère régulatrice de la myosine ventriculaire et, fonctionnellement liée à ladite région promotrice, une séquence d'ADN hétérologue, qui code la protéine phosphatase alcaline sécrétée (SEAP).
- 70 **31.** Vecteur selon la revendication 30, dans lequel ledit promoteur comprend la séquence nucléotidique de SEQ ID NO: 1 ou 2, ou un fragment de celle-ci.
- 75 **32.** Vecteur selon la revendication 30 ou 31, comprenant la séquence nucléotidique de SEQ ID NO: 3.
- 80 **33.** Utilisation d'une région promotrice du gène de la chaîne lourde alpha de la myosine murine ou du gène de la chaîne légère régulatrice de la myosine ventriculaire pour l'expression spécifique de séquences d'ADN hétérologues au cours de l'embryogenèse ou du développement cellulaire, dans un procédé selon l'une quelconque des revendications 1 à 12 ou 23 à 27.




Fig. 1

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 6498018 A [0007]
- WO 02086073 A [0008]
- US 6007993 A [0008]
- WO 9901552 A [0010]
- US 5670372 A [0030]
- US 6245566 A [0056]
- US 20030032185 A [0057]
- US 5523226 A [0059]
- WO 9712035 A [0059]
- WO 0188096 A [0059]
- US 6545199 A [0059]
- US 5773255 A [0061]
- US 5789246 A [0061]
- WO 9616163 A [0076]
- WO 9849320 A [0079]
- WO 0034435 A [0080]
- WO 02095068 A [0080]
- WO 02051987 A [0083] [0087]
- WO 2005005621 A [0089]
- WO 9424274 A [0097]
- US 4670388 A [0098]
- WO 0034525 A [0105]
- WO 03014326 A [0115]
- WO 9506409 A [0115]

Non-patent literature cited in the description

- **Kochhar.** *Limb Buds. Teratology*, 1975, vol. 11, 273-287 [0004]
- **Flint ; Orton.** *Toxicol. Appl. Pharmacol.*, 1984, vol. 76, 383-395 [0004]
- **Laschinski et al.** *Reproductive Toxicol.*, 1991, vol. 5, 57-65 [0005]
- **Newall ; Beedles.** *Toxicol. in Vitro*, 1994, vol. 8, 697-701 [0005]
- **Sehlmeier ; Wobus.** *Mutation Res.*, 1994, vol. 324, 69-76 [0005]
- **Wobus et al.** *J. Mol. Cell. Cardiol.*, 1997, vol. 29, 1525-1539 [0009]
- **Liu et al.** *Biochem. Biophys. Res. Comm.*, 1999, vol. 260, 712-717 [0011] [0045]
- **Kim et al.** *Science*, 1997, vol. 266, 2011 [0024]
- **Thomson et al.** *Science*, 1998, vol. 282, 1145 [0028]
- **Thomson et al.** *Proc. Natl. Acad. Sci. USA*, 1995, vol. 92, 7844 [0028] [0056]
- **Thomson et al.** *Biol. Reprod.*, 1996, vol. 55, 254 [0028]
- **Shablott et al.** *Proc. Natl. Acad. Sci. USA*, 1998, vol. 95, 13726 [0028] [0056]
- **Martin ; Evans.** *Proc. Natl. Acad. Sci. USA*, 1975, vol. 72, 1441-1445 [0029]
- **Schmitt et al.** *Genes Dev.*, 1991, vol. 5, 728-740 [0030]
- **Doetschman et al.** *J. Embryol. Exp. Morph.*, 1985, vol. 87, 27-45 [0030] [0097]
- **Leypoldt et al.** *J. Neurochem.*, 2001, vol. 76, 806-814 [0050]
- **Ezeonu et al.** *DNA Cell Biol.*, 2000, vol. 19, 527-537 [0050]
- **Kees.** *Blood*, 1988, vol. 72, 1524-1529 [0050]
- **Fontana.** *Proc. Natl. Acad. Sci. USA*, 1980, vol. 77, 3664-3668 [0050]
- **Reyes ; Verfaillie.** *Ann. N Y Acad. Sci.*, 2001, vol. 938, 231-235 [0053]
- **Weissman ; Anderson.** *Annu. Rev. Cell Dev. Biol.*, 2001, vol. 17, 387-403 [0053]
- **Anderson et al.** *Nat. Med.*, 2001, vol. 7, 393-395 [0053]
- **Prockop.** *Science*, 1997, vol. 276, 71-74 [0053]
- *Reprod. Biomed. Online*, 2002, vol. 4, 58-63 [0056]
- **Miura et al.** *Proc. Natl. Acad. Sci. USA*, 2003, vol. 100, 5807-5812 [0057]
- **Lin et al.** *Stem Cells*, 2003, vol. 21, 152-161 [0057]
- **Grounds et al.** *J. Histochem. Cytochem.*, 2002, vol. 50, 589-610 [0057]
- **Colman ; Kind.** *Trends Biotechnol.*, 2000, vol. 18, 192-196 [0057]
- **Kiessling ; Anderson.** *Human Embryonic Stem Cells: An Introduction to the Science and Therapeutic Potential.* Jones and Bartlett Publishers, 2003 [0058]
- **Koopman ; Cotton.** *Exp. Cell*, 1984, vol. 154, 233-242 [0060]
- **Smith ; Hooper.** *Devel. Biol.*, 1987, vol. 121, 1-91 [0060]
- **Keller et al.** *Mol. Cell Biol.*, 1993, vol. 13, 473-486 [0061]
- **Palacios et al.** *Proc. Natl. Acad. Sci. USA*, 1995, vol. 92, 7530-7534 [0061]
- **Rich.** *Blood*, 1995, vol. 86, 463-472 [0061]
- **Bain et al.** *Developmental Biology*, 1995, vol. 168, 342-357 [0061]
- **Fraichard et al.** *J. Cell Science*, 1995, vol. 108, 3161-3188 [0061]

- Klug et al. *Am. J. Physiol.*, 1995, vol. 269, H1913-H1921 [0061]
- Rohwedel et al. *Dev. Biol.*, 1994, vol. 164, 87-101 [0061]
- Wang et al. *Development*, 1992, vol. 114, 303-316 [0061]
- Jones et al. *Exp. Cell Res.*, 2002, vol. 272, 15-22 [0061]
- Zhou et al. *J. Cell Sci.*, 1995, vol. 108, 3677-3684 [0067]
- Gory et al. *Blood*, 1999, vol. 93, 184-192 [0067]
- Quinn et al. *Biochem. Biophys. Res. Commun.*, 2000, vol. 276, 1089-1099 [0067]
- Schlaeger et al. *Proc. Natl. Acad. Sci. USA*, 1997, vol. 94, 3058-3063 [0067]
- Kappel et al. *Blood*, 1999, vol. 93, 4284-4292 [0067]
- Gloster et al. *J. Neurosci.*, 1994, vol. 14, 7319-7330 [0067]
- Besnard et al. *J. Biol. Chem.*, 1991, vol. 266, 18877-18883 [0067]
- Kallmeier et al. *J. Biol. Chem.*, 1995, vol. 270, 30949-30957 [0067]
- Song et al. *J. Neurochem.*, 1997, vol. 68, 792-803 [0067]
- Yamazaki et al. *J. Mol. Cell Cardiol.*, 1995, vol. 27, 133-140 [0071]
- Johnson et al. *Biochem. Pharmacol.*, 1993, vol. 45, 2365-2372 [0071]
- Niwa et al. *Gene*, 1991, vol. 108, 193-199 [0073]
- Wobus et al. *J. Mol. Cell Cardiol.*, 1997, vol. 29, 1525-1539 [0073]
- Metzger et al. *Circ. Res.*, 1996, vol. 78, 547-552 [0073]
- Lints et al. *Development*, 1993, vol. 119, 419-431 [0076]
- Sartorelli et al. *Genes Dev.*, 1990, vol. 4, 1811-1822 [0076]
- O'Brien et al. *Proc. Natl. Acad. Sci. USA.*, 1993, vol. 90, 5157-5161 [0076]
- Lee et al. *Mol. Cell Biol.*, 1994, vol. 14, 1220-1229 [0076]
- Franz et al. *Circ. Res.*, 1993, vol. 73, 629-638 [0076]
- Palermo et al. *Cell Mol. Biol. Res.*, 1995, vol. 41, 501-519 [0076] [0139]
- Gulick et al. *J. Biol. Chem.*, 1991, vol. 266, 9180-91855 [0076] [0139]
- Yutzey et al. *Development*, 1994, vol. 120, 871-883 [0076] [0142]
- Yang et al. *Biotechniques*, 1997, vol. 23, 1110-1114 [0078]
- Schlatter et al. *Gene*, 2002, vol. 282, 19-31 [0079] [0081]
- Mace et al. *Virology*, 1992, vol. 188, 869-874 [0079]
- Wang et al. *Gene*, 2001, vol. 279, 99-108 [0080]
- Bronstein et al. *Biotechniques*, 1994, vol. 17, 172-177 [0080]
- Nilsson et al. *Cancer Chemother. Pharmacol.*, 2002, vol. 49, 93-100 [0080]
- Chu et al. *Biotechniques*, 1995, vol. 5, 890-896 [0081]
- Kamiya et al. *Tohoku J. Exp. Med.*, 1996, vol. 180, 297-308 [0081]
- Blau et al. *Blood*, 1997, vol. 89, 146-154 [0082]
- Embryonic Stem Cells: Research and Clinical Potentials. Snodgrass et al. Peripheral Blood Stem Cells. American Association of Blood Banks, 1993 [0084]
- Wobus et al. *Differentiation*, 1991, vol. 48, 172-182 [0087]
- Wartenberg et al. *FASEB J.*, 2001, vol. 15, 995-1005 [0088]
- Williams. *Environ. Health Perspect.*, 1978, vol. 22, 133-138 [0090]
- Duncan. *Adv. Sci.*, 1967, vol. 23, 537-541 [0090]
- Gene Targeting. A Practical Approach. Oxford University Press, 1993 [0097]
- McMahon ; Bradley. *Cell*, 1990, vol. 62, 1073-1085 [0097]
- Robertson. Teratocarcinomas and Embryonic Stem Cells: A Practical Approach. IRL Press, 1987, 71-112 [0097]
- Hooper et al. *Nature*, 1987, vol. 326, 292-295 [0097]
- Robertson et al. *Nature*, 1986, vol. 323, 445-448 [0097]
- Zhuang et al. *Cell*, 1994, vol. 77, 875-884 [0097]
- Sunaga et al. *Mol. Reprod. Dev.*, 1997, vol. 46, 109-113 [0097]
- Brand ; Perrimon. *Development*, 1993, vol. 118, 401-415 [0098]
- Phelps ; Brand. *Methods*, 1998, vol. 14, 367-379 [0098]
- Mello et al. *EMBO J.*, 1991, vol. 10, 3959-3970 [0098]
- Plasterk. *Methods Cell. Biol.*, 1995, vol. 48, 59-80 [0098]
- Ostresh. *Methods in Enzymology*, 1996, vol. 267, 220-234 [0111]
- Domer. *Bioorg. Med. Chem.*, 1996, vol. 4, 709-715 [0111]
- *Nat. Rev. Drug Discov.*, 2002, vol. 1, 26-36 [0111]
- *Drug Discov. Today*, 2002, vol. 7, 117-125 [0111]
- Wartenberg et al. *Lab. Invest.*, 2003, vol. 83, 87-98 [0112]
- Sundberg. *Curr. Opin. Biotechnol.*, 2000, vol. 11, 47-53 [0121]
- Verlinde ; Hol. *Structure*, 1994, vol. 2, 577-587 [0121]
- Salemme et al. *Structure*, 1997, vol. 15, 319-324 [0121]
- Rein. Computer-Assisted Modeling of Receptor-Ligand Interactions. Alan Liss, 1989 [0121]
- Beilstein. Handbook of Organic Chemistry. Springer edition New York Inc, [0121]
- Organic Synthesis. Wiley [0121]
- Cheng et al. *J. Am. Chem. Soc.*, 1995, vol. 117, 8859-8860 [0121]
- Fejzo et al. *Chem. Biol.*, 1999, vol. 6, 755-769 [0121]

- **Lin et al.** *J. Org. Chem.*, 1997, vol. 62, 8930-8931 [0121]
- **Kubinyi.** *J. Med. Chem.*, 1993, vol. 41, 2553-2564 [0121]
- **Kubinyi.** *Pharm. Unserer Zeit*, 1994, vol. 23, 281-290 [0121]
- **Holzgrabe ; Bechtold.** *Pharm. Acta Helv.*, 2000, vol. 74, 149-155 [0121]
- **Meyer.** *J. Pharmacokinet. Biopharm.*, 1996, vol. 24, 449-459 [0123]
- **Ozama.** *J. Toxicol. Sci.*, 1996, vol. 21, 323-329 [0123]
- **Guan et al.** *Altex*, 1999, vol. 16, 135-141 [0132]
- **Berks.** *TIBTECH*, 1994, vol. 12, 352-364 [0134]
- A practical approach. IRL Press Ltd, 1987 [0137]
- Guide to Techniques in Mouse Development. Academic Press, 1993 [0137]
- **Wiles.** *Meth. Enzymol.*, 1993, vol. 225, 900 [0137]
- **Rathjen et al.** *Reprod. Fertil. Dev.*, 1998, vol. 10, 31 [0137]
- **Robertson.** *Meth. Cell Biol.*, 1997, vol. 75, 173 [0137]
- **Pedersen.** *Reprod. Fertil. Dev.*, 1998, vol. 10, 31 [0137]
- **Evans ; Kaufman.** *Nature*, 1981, vol. 292, 154-156 [0137]
- **Handyside et al.** *Roux's Arch. Dev. Biol.*, 1987, vol. 196, 185-190 [0137]
- **Flechon et al.** *J. Reprod. Fertil. Abstract Series 6*, 1990, 25 [0137]
- **Doetschman et al.** *Dev. Biol.*, 1988, vol. 127, 224-227 [0137]
- **Evans et al.** *Theriogenology*, 1991, vol. 33, 125-128 [0137]
- **Notarianni et al.** *J. Reprod. Fertil. Suppl.*, 1991, vol. 43, 255-260 [0137]
- **Giles et al.** *Biol. Reprod.*, 1991, vol. 44 (1), 57 [0137]
- **Strelchenko et al.** *Theriogenology*, 1991, vol. 35, 274 [0137]
- **Sukoyan et al.** *Mol. Reprod. Dev.*, 1992, vol. 93, 418-431 [0137]
- **Iannaccone et al.** *Dev. Biol.*, 1994, vol. 163, 288-292 [0137]
- **Sambrook et al.** *Molecular Cloning: A Laboratory Manual.* Cold Spring Harbor Laboratory Press, 1989 [0138]
- DNA Cloning. 1985, vol. I, II [0138]
- Oligonucleotide Synthesis [0138]
- Nucleic Acid Hybridization. 1984 [0138]
- Transcription And Translation [0138]
- **R. I. Freshney.** *Culture Of Animal Cells.* Alan R. Liss, Inc, 1987 [0138]
- Gene Transfer Vectors for Mammalian Cells [0138]
- Current Protocols in Molecular Biology and Short Protocols in Molecular Biology [0138]
- Recombinant DNA Methodology. Academic Press [0138]
- Gene Transfer Vectors For Mammalian Cells. Cold Spring Harbor Laboratory, 1987 [0138]
- Methods In Enzymology. vol. 154, 155 [0138]
- Immobilized Cells And Enzymes. IRL Press [0138]
- **B. Perbal.** *A Practical Guide To Molecular Cloning.* 1984 [0138]
- Methods In Enzymology. Academic Press, Inc, [0138]
- Immunochemical Methods In Cell And Molecular Biology. Academic Press, 1987 [0138]
- Handbook Of Experimental Immunology. 1986, vol. I-IV [0138]
- **Hu et al.** *Curr. Opin. Biotechnol.*, 1997, vol. 8, 148 [0138]
- **Kitano.** *Biotechnology*, 1991, vol. 17, 73 [0138]
- *Curr. Opin. Biotechnol.*, 1991, vol. 2, 375 [0138]
- **Birch et al.** *Bioprocess Technol.*, 1990, vol. 19, 251 [0138]
- **Morkin.** *Microsc. Res. Tech.*, 2000, vol. 50, 522-531 [0139]
- **Boheler et al.** *Circ. Res.*, 2002, vol. 91, 189-201 [0139]
- **Berger et al.** *Gene*, 1988, vol. 66, 1-10 [0139]
- **Torres ; Kühn.** *Laboratory protocols for conditional gene targeting.* Oxford University Press, 1997 [0141]
- **Osmond et al.** *Development*, 1991, vol. 113, 1405-1417 [0142]
- **Dickman ; Smith.** *Dev. Dyn.*, 1996, vol. 206, 39-48 [0142]
- **Drysdale et al.** *Dev. Biol.*, 1997, vol. 188, 205-215 [0142]
- **Seiler et al.** *ALTEX*, 2002, vol. 19 (1), 55-63 [0142]